Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 1602. Отображено 100.
01-03-2012 дата публикации

Reagent kit for detecting lupus anticoagulant and method of determining presence or absence of lupus anticoagulant

Номер: US20120052585A1
Автор: Kazuyo Yoshida, Masahiro Okuda, Osamu Kumano
Принадлежит: Sysmex Corp

The present invention provides a reagent kit for detecting LA which includes a first clotting time-measuring reagent containing manganese salt and a second clotting time-measuring reagent which contains manganese salt at a concentration lower than that of the first clotting time-measuring reagent or does not contain manganese salt and a method of determining the presence or absence of LA using the kit.

Подробнее
Номер записи: 1
19-04-2012 дата публикации

diagnostic method

Номер: US20120091333A1
Автор: Dharmica April Harridatt Mistry, Gary L. Corino, Joseph Haklani, Peter William French
Принадлежит: Sbc Research Pty Ltd

The present invention relates to methods to identify one or more conditions in a subject. In particular, it relates to methods of identifying a condition such as cancer, which changes a lipid profile in a keratin-containing component of a subject, the changes to the lipid profile being determined by techniques such as chromatography and mass spectrometry.

Подробнее
Номер записи: 2
09-08-2012 дата публикации

Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis

Номер: US20120202188A1
Автор: Elodie Pastural, Shawn Ritchie
Принадлежит: Phenomenome Discoveries Inc

Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.

Подробнее
Номер записи: 3
04-10-2012 дата публикации

Real time multipoint assay for optimizing performance

Номер: US20120252000A1
Автор: Barb Ariel Cohen
Принадлежит: Barb Ariel Cohen

Described herein are methods of optimizing the performance of a mammalian semen sample with respect to outcomes such as fertility, using a multipoint assay to determine an optimum time point for preparing the semen sample for use in insemination. The multipoint assay is based upon a kinetic model of biomarker expression during sperm capacitation relative to the outcome of interest.

Подробнее
Номер записи: 4
31-01-2013 дата публикации

Method for avoiding influence of endogenous lipoprotein and reagent

Номер: US20130029429A1
Автор: Takayuki Abe, Tetsuya Ota, Yuki Takahashi
Принадлежит: Sekisui Medical Co Ltd

To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component.

Подробнее
Номер записи: 5
28-03-2013 дата публикации

Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists

Номер: US20130079309A1
Автор: Joe G.N. Garcia, Steven M. Dudek
Принадлежит: University of Illinois

The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation.

Подробнее
Номер записи: 6
22-08-2013 дата публикации

Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses

Номер: US20130216553A1
Автор: Frank C. Nichols, Robert B. Clark
Принадлежит: University of Connecticut

A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison is indicative of the inflammatory or the autoimmune condition. An example of the autoimmune condition is multiple sclerosis. According to one embodiment, an increased ratio of phosphoglycerol dihydroceramide (PG DHC) to phosphoethanolamine dihydroceramide (PE DHC) in a blood sample indicates a presence of MS in the source patient. The use of PDHCs as biomarkers for detection of MS is described. Antibodies specific to PG DHC or PE DHC are also provided, along with their uses. Also provided are compositions comprising bacteria-originated lipids useful for modulation of immune responses or TLR pathways in humans, animals, and human or animal cells or tissues.

Подробнее
Номер записи: 7
05-01-2017 дата публикации

METHODS FOR DETECTING, DIAGNOSING AND TREATING ENDOMETRIAL CANCER

Номер: US20170003291A1
Автор: Bahado-Singh Ray
Принадлежит:

The present invention relates to methods for detecting, diagnosing and/or treating endometrial cancer by detecting in a biological sample from a patient the levels of one or more of the metabolites: C14.2, PC ae C38:1, 3-Hydroxybutyric acid, C18:2, PC ae C40:1, and C6 (C4:1-DC). In some embodiments, the method also includes diagnosing the patient with endometrial cancer when the one or more metabolites in the biological sample is at a different level than a statistically validated threshold for the one or more metabolites, and ultrasound indicates endometrial cancer in the patient. In further embodiments, once endometrial cancer is diagnosed, the patient is treated for the endometrial cancer. 1. A method of detecting a level of two or more metabolites in a biological sample , said method consisting of:obtaining a biological sample from a human patient, wherein said biological sample includes two or more of C14.2, PC ae C38:1, 3-Hydroxybutyric acid, C18:2, PC ae C40:1, and C6 (C4:1-DC); anddetecting the level of the two or more metabolites in the biological sample.2. The method of claim 1 , wherein the sample is blood serum.3. The method of claim 1 , wherein the two or more metabolites are C14.2 claim 1 , PC ae C38:1 claim 1 , and 3-Hydroxybutyric acid.4. The method of claim 1 , wherein the two or more metabolites are C18:2 claim 1 , PC ae C40:1 claim 1 , and C6 (C4:1-DC).5. The method of claim 1 , wherein the level of the two or more metabolites are detected by performing Magnetic Resonance spectroscopy (MRS) using a magnetic resonance imaging (MRI) machine claim 1 , nuclear magnetic resonance (NMR) claim 1 , or mass spectrometry (MS) on the biological sample.6. The method of wherein the two or more metabolites are detected by magnetic resonance spectroscopy (MRS).7. The method of claim 6 , wherein the MRS is proton magnetic resonance spectroscopy (1H-MRS)8. A method of diagnosing endometrial cancer in a human patient claim 6 , wherein said human patient has a ...

Подробнее
Номер записи: 8
07-01-2016 дата публикации

USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS

Номер: US20160003855A1
Автор: Bowen Benjamin P., LOUIE Katherine B., NORTHEN Trent R.
Принадлежит:

Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. 1. A method for identifying one or more diseased cells in a subject , comprising:(a) providing a biological sample derived from a subject;(b) analyzing the biological sample by mass spectrometry; and(c) determining the abundance of one or more lipids in the biological sample, wherein an altered abundance of the one or more lipids in the biological sample, as compared to a reference level, indicates a presence of one or more diseased cells in the subject from which the biological sample is derived.2. The method of claim 1 , wherein the reference level is established using a reference sample from a healthy subject.3. (canceled)4. (canceled)5. The method of claim 1 , wherein the biological sample comprises a tissue sample claim 1 , a bodily fluid claim 1 , a cell culture or extracts thereof claim 1 , or a combination thereof.6. (canceled)7. (canceled)8. The method of claim 1 , wherein the biological sample comprises one or more lipid-containing microparticles.9. The method of claim 8 , wherein the one or more lipid-containing microparticles are exosomes claim 8 , cell membrane fragments claim 8 , cellular and intracellular organelle fragments claim 8 , lipid bilayers claim 8 , or a combination thereof.10. (canceled)11. (canceled)12. The method of claim 8 , wherein analyzing the biological sample by mass spectrometry comprises isolating the one or more lipid-containing microparticles from the biological sample and analyzing the lipid-containing microparticles by mass spectrometry.13. The method of claim 12 , wherein the isolating step comprises isolating the one or more lipid-containing microparticles from the biological sample by filtration claim 12 , centrifugation claim 12 , microfluidics claim 12 , antibody affinity capture claim 12 , or a ...

Подробнее
Номер записи: 9
07-01-2021 дата публикации

LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE

Номер: US20210003598A1
Автор: Ekroos Kim, Hurme Reini, Katainen Riikka, Laaksonen Reijo
Принадлежит:

The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD. 125.-. (canceled)26. A method for determining whether a subject is at risk to develop , or is suffering from atherosclerosis or cardiovascular disease (CVD) and/or one or more of their complications , comprising:(a) determining in a sample from said subject the concentration(s) of one or more lipid(s), wherein (an) increased or decreased concentration(s) in said sample, when compared to a control sample, is (are) indicative of said subject suffering from or having an increased risk of developing atherosclerosis or CVD and/or one or more of their complications, wherein the one or more lipid(s) whose increase(s) in concentration is (are) compared to the control is (are) selected from: Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1), Cer(d18:1/20:0), Cer(d18:0/24:1), LacCer(d18:1/18:0), LacCer(d18:1/20:0), LacCer(d18:1/22:0), LacCer(d18:1/24:1), GlcCer(d18:1/16:0), GlcCer(d18:1/18:0), Total Cer, Total LacCer and Total GlcCer; andwherein the one or more lipid(s) whose decrease(s) is (are) compared to the control is (are) selected from: Cer(d18:1/26:0), PC 16:0/16:1, PC 16:0/18:2, PC 16:0/20:4, PC 16:0/20:5, PC 16:0/22:5, PC 16:0/22:6, PC 18:0/20:3, PC 18:0/20:5, PC 35:3 (PC O-34:3), PC 37:5 (PC O-38:5), PC 40:5, PI 38:3, PI 38:4, SM (d18:1/15:0) (d18:1/14:1-OH), SM (d18 ...

Подробнее
Номер записи: 10
01-01-2015 дата публикации

METHODS AND KITS FOR DETERMINING RISK FOR DEVELOPING ALZHEIMER'S DISEASE AND PREVENTION OR TREATMENT THEREOF

Номер: US20150005351A1
Автор: Castello Michael, Soriano Salvador
Принадлежит:

Methods are disclosed for determining a patient's risk for developing Alzheimer's disease and preventing or treating Alzheimer's disease. Kits for assessing a patient's risk of developing Alzheimer's are also provided. 1. A method for determining a patient's risk of developing Alzheimer's disease , comprising:obtaining a test sample from the patient;combining the test sample with an intracellular cholesterol staining reagent to form a labeled cholesterol complex;estimating a concentration of intracellular cholesterol in the test sample by quantifying the amount of labeled cholesterol complex in the test sample; andcomparing the estimated concentration of intracellular cholesterol in the test sample with a concentration of intracellular cholesterol in a control sample, wherein a greater concentration of intracellular cholesterol in the test sample compared to the control sample indicates an increased risk of developing Alzheimer's disease.2. The method of claim 1 , wherein the patient suffers from mild cognitive impairment.3. The method of claim 1 , wherein the intracellular cholesterol staining reagent is selected from filipin claim 1 , BCθ and Amplex® red reagent.4. The method of claim 3 , wherein the staining reagent is filipin.5. The method of claim 4 , wherein flow cytometry is used to quantify the amount of filipin-labeled cholesterol complex in the test sample.6. The method of claim 5 , wherein the test sample comprises peripheral blood cells.7. A method for preventing or delaying the onset of Alzheimer's disease claim 5 , or reducing the symptoms of Alzheimer's disease in a patient in need thereof claim 5 , comprising:obtaining a test sample from the patient;determining a level of intracellular cholesterol in the test sample; andcomparing the level of intracellular cholesterol in the test sample with a control level of intracellular cholesterol,identifying at least one cholesterol defect or distress of the patient; andadministering at least one therapeutic ...

Подробнее
Номер записи: 11
03-01-2019 дата публикации

SERUM-BASED BIOMARKERS OF PANCREATIC CANCER AND USES THEREOF FOR DISEASE DETECTION AND DIAGNOSIS

Номер: US20190004049A1
Автор: Pastural Elodie, Ritchie Shawn
Принадлежит:

Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described. 118.-. (canceled)20. The method of claim 19 , wherein the one or more than one metabolite marker is a combination of metabolite markers that further comprises a marker having the molecular formula of CHOand being characterized by a CID MS/MS fragmentation pattern using Nas collision gas and analyzed under negative ionization comprising the following daughter ions: 593.5 claim 19 , 557.5 claim 19 , 575.4 claim 19 , 549.4 claim 19 , 531.5 claim 19 , 513.4 claim 19 , 495.4 claim 19 , 433.3 claim 19 , 421.4 claim 19 , 415.2 claim 19 , 391.4 claim 19 , 371.3 claim 19 , 315.3 claim 19 , 311.1 claim 19 , 297.2 claim 19 , 281.2 claim 19 , 277.2 claim 19 , 251.2 claim 19 , 201.1 claim 19 , 195.3 claim 19 , 171.1 claim 19 , 139.1 and 133.5.21. The method of claim 19 , wherein the one or more than one metabolite marker is the lysophosphatidylcholine LysoPC 20:5 claim 19 , having a molecular formula of CHNOP.22. The method of claim 19 , wherein the one or more than one metabolite marker is the phosphatidylcholine having a molecular formula of CHNOP.23. The method of claim 19 , wherein the one or more than one metabolite marker is the phosphatidylcholine having a molecular formula of CHNOP.24. The method of claim 19 , wherein the one or more than one metabolite ...

Подробнее
Номер записи: 12
13-01-2022 дата публикации

Method for the Diagnosis of Gaucher's Disease

Номер: US20220011321A1
Автор: Mascher Hermann, Rolfs Arndt
Принадлежит:

The present invention is related to an in vitro method for diagnosing Gaucher's disease in a subject comprising a step of 116-. (canceled)17. A method for generating quantitative data for a subject comprising the step of determining at several points in time a level of a biomarker present in a sample from the subject , wherein the biomarker is free lyso-Gb1 , and wherein the level of the biomarker is indicative of the severity of the disease in the subject.18. The method of claim 17 , wherein the sample is selected from the group consisting of a blood sample claim 17 , a serum sample claim 17 , a plasma sample claim 17 , a whole blood sample and a sample from whole blood collected on a dry blood filter card.19. The method of claim 17 , wherein the subject has been previously treated or diagnosed for Gaucher's disease.20. The method of claim 17 , wherein the level of the biomarker present in the sample from the subject is determined on a regular basis.21. The method of claim 17 , wherein the level of the biomarker present in the sample from the subject is determined every 3 months or every 6 months.22. The method of claim 17 , wherein free lyso-Gb1 is lyso-Gb1 as present in the subject and not the result of manipulating the sample from the subject.23. The method of claim 17 , wherein the blood sample is a full blood sample or a dry blood filter sample.24. The method of claim 17 , wherein the biomarker is detected by means of mass spectrometry analysis claim 17 , immunoassay claim 17 , biochip array claim 17 , functional nucleic acids and/or a fluorescent derivative of free lyso-Gb1.25. The method of claim 24 , wherein the biomarker is detected by means of mass spectrometry.26. The method of claim 17 , wherein at each of the several points in time a separate sample is taken from the subject and the level of the biomarker is determined in the separate sample. The present invention is related to a method for diagnosing Gaucher's disease in a subject, a method for ...

Подробнее
Номер записи: 13
08-01-2015 дата публикации

Method for determining liver fat amount and method for diagnosing nafld

Номер: US20150011424A1
Автор: Gopalacharyulu Peddinti, Hannele YKI-JÄRVINEN, Matej Oresic, Sandra CASTILLO, Tuulia HYÖTYLÄINEN
Принадлежит: Valtion teknillinen tutkimuskeskus

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and/or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

Подробнее
Номер записи: 14
12-01-2017 дата публикации

METHODS OF DETERMINING A HIGH DENSITY LIPOPROTEIN PHOSPHOLIPID LEVEL IN A SAMPLE

Номер: US20170010290A1
Автор: Ashmaig Mohmed E., Warnick George Russell
Принадлежит:

The present disclosure provides economical and scalable (e.g., high-throughput) methods of determining an HDL-PL level in a sample from a subject, and methods of treating a subject comprising determining an HDL-PL level in a sample from the subject. 1. A method of determining a level of HDL-PL associated with a subject , the method comprising:removing non-HDL lipoproteins from a sample associated with the subject to produce a purified HDL-PL composition;contacting the purified HDL-PL composition with an indicator system; andmeasuring a concentration of the HDL-PL as a function of at least an absorbance of the indicator system.2. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises contacting the sample with a precipitation reagent comprising dextran claim 1 , a Mgsalt and sodium azide.3. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises contacting the sample with apolipoprotein B antisera to immunoprecipitate non-HDL particles.4. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises ultracentrifuging the sample and thereafter removing any fractions having a density of at least 1.063 g/mL.5. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises gel filtration of the sample.6. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises gel filtering the sample.7. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises filtering the sample through a column.8. The method of claim 1 , wherein the step of removing non-HDL lipoproteins comprises contacting the sample with cholesterol oxidase claim 1 , peroxidase claim 1 , phospholipidase D and N claim 1 ,N-bis-(4-sulfobutyl)-m-toulidine disodium.9. The method of claim 1 , wherein the indicator system comprises phospholipase D claim 1 , choline oxidase claim 1 , N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3 claim 1 ,5-dimethoxyaniline claim 1 , 4- ...

Подробнее
Номер записи: 15
10-01-2019 дата публикации

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF ADRENOLEUKODYSTROPHY

Номер: US20190010535A1
Автор: FOURCADE Stephane, JOVE FONT Mariona, LOPEZ DE MUNAIN ARREGI Adolfo Jose, PAMPLONA GRAS Reinaldo, PORTERO OTIN Manuel, PUJOL ONOFRE Aurora
Принадлежит:

The present invention is directed to a diagnostic method for adrenoleukodystrophy in a subject based on the determination of the levels of different markers. The invention also provides a method for monitoring the progression of an adrenoleukodystrophy, a method for monitoring the effect of an adrenoleukodystrophy therapy and fingolimod, an analogue, metabolite or derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of anadrenoleukodystrophy. 1. (canceled)4. The method according to wherein the therapy comprises an antioxidant compound.5. The method according to wherein the antioxidant compound is a combination of N-acetylcysteine claim 4 , lipoic acid and vitamin E.6. The method according to wherein the adrenoleukodystrophy occurs without inflammatory demyelination.7. The method according to wherein the sample is a sample containing peripheral mononuclear cells.8. The method according to wherein the adrenoleukodystrophy is selected from the group consisting of adult adrenomyeloneuropathy (AMN) claim 2 , cerebral adrenomyeloneuropathy (cAMN) and the childhood variant of drenoleukodystrophy (cALD).920-. (canceled)21. A method for the treatment and/or prevention of an adrenoleukodystrophy in a subject in need thereof comprising the administration of an inhibitor of sphingosine-1-phosphate receptor 1 or a pharmaceutical composition comprising said inhibitor.22. The method according to claim 21 , wherein said inhibitor is fingolimod claim 21 , an analogue claim 21 , metabolite or derivative thereof claim 21 , or a pharmaceutically acceptable salt thereof.23. The method according to wherein the fingolimod analogue is siponimod.24. The method according to wherein the adrenoleukodystrophy is selected from the group consisting of adult adrenomyeloneuropathy (AMN) claim 21 , cerebral adrenomyeloneuropathy (cAMN) and the childhood variant of adrenoleukodystrophy (cALD).25. The method according to wherein the ...

Подробнее
Номер записи: 16
14-01-2021 дата публикации

QUANTIFICATION METHOD, QUANTIFICATION REAGENT AND QUANTIFICATION KIT FOR LIPOPROTEIN CHOLESTEROL

Номер: US20210011036A1
Автор: Hirao Yuhko, IKAIDA Makoto, Satoh Noriyuki
Принадлежит: Denka Company Limited

Provided are a method which enables more accurate quantification of lipoprotein cholesterol in a test sample, and a quantification reagent and a quantification kit used for this method. The present invention provides a quantification method for lipoprotein cholesterol in a test sample containing a lipoprotein optionally using a quantification reagent, the method including adding a phospholipid to the test sample or the quantification reagent. The present invention also provides a quantification reagent for cholesterol in a lipoprotein used in the method of the present invention, the quantification reagent containing a phospholipid. The present invention also provides a quantification kit for lipoprotein cholesterol used in the method of the present invention, the quantification kit containing a phospholipid. 1. A method for quantifying lipoprotein cholesterol in a test sample containing a lipoprotein optionally using a quantification reagent , the method comprising adding a phospholipid to the test sample or the quantification reagent.2. The method according to claim 1 , wherein the phospholipid is phosphatidylcholine (PC) or lysophosphatidylcholine (LPC).3. The method according to claim 1 , wherein the phospholipid is a phospholipid-like surfactant.4. The method according to claim 1 , wherein the phospholipid is a lipoprotein which is different from the lipoprotein containing the cholesterol to be quantified.5. The method according to claim 4 , wherein the phospholipid is high-density lipoprotein (HDL).6. The method according to claim 1 , wherein the lipoprotein is triglyceride-rich lipoprotein (TRL).7. The method according to claim 1 , wherein the lipoprotein is small claim 1 , dense LDL.8. The method according to claim 1 , wherein the lipoprotein cholesterol is quantified using a quantification reagent.9. A reagent for quantifying cholesterol in a lipoprotein claim 1 , used in the method according to claim 1 , the quantification reagent comprising a phospholipid. ...

Подробнее
Номер записи: 17
03-02-2022 дата публикации

ASSAYS FOR DETECTING MODIFIED COMPOUNDS

Номер: US20220034897A1
Автор: Pande Praveen, Rabbani Elazar, Rabbani Joshua, Stavrianopoulos Jannis G.
Принадлежит: ENZO LIFE SCIENCES, INC.

Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest. 1. A method for detecting or quantifying an enzyme capable of adding a functional group to a compound in a sample , comprising the steps of: (i) a compound which can gain a functional group from an enzyme, the compound comprising at least one non-radioactive signaling moiety;', '(ii) a sample suspected of containing an enzyme that could add a functional group to the compound; and, '(a) providing(b) forming a mixture comprising the compound and the sample; and(c) separating any compound that has gained the functional group; and(d) detecting or quantifying the non-radioactive signaling moiety of any separated compounds having the functional group, thereby detecting or quantifying the enzyme in the sample.2. The method of claim 1 , wherein the enzyme is selected from the group comprising kinases claim 1 , phosphatases claim 1 , sulfatases claim 1 , sufotransferases claim 1 , acetyltransferases claim 1 , deacetylases claim 1 , methylases claim 1 , demethylases claim 1 , carboxylases claim 1 , decarboxylases claim 1 , glycosylases claim 1 , amidases claim 1 , deamidases claim 1 , aminases and deaminases.3. The method of claim 1 , wherein the enzyme is selected from the group comprising kinases claim 1 , phosphatases claim 1 , or sulfotransferases.4. The method of claim 1 , wherein the enzyme is sphingosine kinase 1 or sphingosine kinase 2.5. The method of claim 1 , wherein the enzyme is sphingosine kinase 1.6. The method of claim 1 , wherein the enzyme is sphingosine kinase 2.7. The method of claim 1 , wherein the non-radioactive signaling moiety comprises a fluorescent compound claim 1 , a ...

Подробнее
Номер записи: 18
21-01-2016 дата публикации

NON-HIGH DENSITY LIPOPROTEIN DERIVED CVD MARKERS

Номер: US20160018423A1
Автор: Laaksonen Reijo
Принадлежит:

The present invention inter alia relates to methods and uses involving the determination of lipid/lipid concentration ratios in order to diagnose, predict, prevent and/or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid/lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control.

Подробнее
Номер записи: 19
16-01-2020 дата публикации

METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS

Номер: US20200017911A1
Автор: Wilson D. Travis
Принадлежит:

The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling. 1. A method for selecting a diagnosing heart failure subject for treatment with an aromatic-cationic peptide , the method comprising; ,(a) detecting levels of monolysocardiolipin acyltransferase (MLCL AT1) acyl-CoA lysocardiolipin (ALCAT1) mRNA in a biological sample from the subject; and(b) selecting the subject for aromatic-cationic peptide treatment where the level of MLCL AT1 or ALCAT1 mRNA in the biological sample from the subject is elevated about 2.5-fold compared to the normal control sample.25.-. (canceled)6. The method of claim 1 , further comprising detecting levels of cardiolipin isoforms in a biological sample from the subject and comparing the levels of cardiolipin isoforms to those of a normal control subject claim 1 , wherein the detecting levels of cardiolipin isoforms comprises chromatography claim 1 , mass spectrometry claim 1 , ELISA claim 1 , Western blotting claim 1 , immunodetection claim 1 , or immuunoprecipitation.7. The method of claim 1 , wherein detecting the level of MLCL AT1 or ALCAT1 mRNA comprises RT-PCR claim 1 , in situ hybridization claim 1 , or Northern blotting.810.-. (canceled)11. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of the aromatic-cationic peptide claim 1 ,wherein the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NHor a pharmaceutically acceptable salt thereof.12. The method of claim 11 , wherein the peptide is administered daily for 6 weeks or more.13. (canceled)14. The method of claim 1 , wherein the heart failure results from hypertension; ischemic heart disease; exposure to a cardiotoxic compound; myocarditis; thyroid ...

Подробнее
Номер записи: 20
28-01-2016 дата публикации

DETECTION OF BRCA CARRIERS IN BREAST TISSUE

Номер: US20160022197A1
Автор: Clarke David, Malycha Peter, Mountford Carolyn, Ramadan Saadallah, Santamaria Gorane
Принадлежит:

A method and system for detecting the presence of BRCS carriers in breast tissue, comprises obtaining spectral data from breast tissue using a magnetic resonance spectroscopy device and producing spectral data by said device which provides chemical markers to enable detection of whether the breast tissue contains BRCA carriers. 1. A method of detecting the presence of BRCS carriers in breast tissue , comprising:obtaining spectral data from breast tissue using a magnetic resonance spectroscopy device;producing spectral data by said device which provides chemical markers to enable detection of whether the breast tissue contains BRCA carriers.2. The method of claim 1 , wherein the spectral data is produced using a 2D COSY.3. The method of claim 1 , wherein the step of producing spectral data produces spectral data which enables detection of whether the breast tissue contains BRCA carriers claim 1 , is normal healthy tissue claim 1 , or contains invasive cancer.4. The method of claim 1 , wherein the spectral data produced enables detection of increased saturated lipid and increased membrane cholesterol which is conducive to tumor growth which constitutes a premalignant condition.5. The method of claim 1 , wherein the step of obtaining spectral data from breast tissue comprises obtaining spectral data from a breast tissue in vivo.6. The method of claim 1 , wherein the step of obtaining spectral data from breast tissue comprises obtaining spectral data from a core fine needle biopsy of breast tissue ex vivo.7. The method of claim 1 , wherein the step of producing spectral data includes producing a spectral image on a display.8. A system for detecting the presence of BRCA carriers in breast tissue claim 1 , comprising:a magnetic resonance spectroscopy device for obtaining spectral data from breast tissue, and;a processor for producing spectral data which includes chemical markers to enable detection of whether the breast tissue contains BRCA carriers.9. The system of claim ...

Подробнее
Номер записи: 21
22-01-2015 дата публикации

METHOD FOR THE ASSAY OF SYNUCLEINS

Номер: US20150024419A1
Автор: SHARON Ronit
Принадлежит:

The present invention provides a method for the assay of synucleins in a body fluid or tissue sample, wherein said method comprises the steps of contacting said sample with membrane lipids under conditions enabling binding of the synuclein to said lipids, and the detection of the lipid-bound synuclein by a synuclein-binding agent. 1. A method for the assay of synucleins in a sample of a biological fluid , wherein said method comprises the steps of contacting said sample with immobilized lipids coating wells under conditions enabling binding of the synuclein to said immobilized lipids , washing the wells , and detection of the lipid-bound immobilized synuclein present on the immobilized lipids by a synuclein-binding agent.2. The method according to claim 1 , wherein the synuclein is selected from the group consisting of alpha claim 1 , beta and gamma synuclein.3. The method according to claim 1 , wherein the synuclein to be detected is α-Syn.4. The method according to claim 1 , wherein the lipids are selected from the group consisting of naturally occurring claim 1 , purified or synthetic phospholipids claim 1 , glycolipids claim 1 , plasmalogenes claim 1 , sphingolipids claim 1 , cholesterol claim 1 , glycolipids or a combination thereof.5. The method according to claim 4 , wherein the lipids are selected from the group consisting of at least one of phosphatidyl inositol claim 4 , phosphatidyl serine phosphatidic acid; phosphatdylethanolamine claim 4 , phosphatidylcholine claim 4 , phosphatidylserine claim 4 , phosphatidylglycerol claim 4 , phosphoinositides claim 4 , cardiolipin claim 4 , ceramide claim 4 , sphingomyelin claim 4 , ether-phospholipids claim 4 , glucosylcerebrosidase claim 4 , galactosylceramide lactosylceramide claim 4 , gangliosides claim 4 , cholesterol claim 4 , cholesterol-ester claim 4 , triglycerides claim 4 , diglycerides and monoglycerides.6. The method according to claim 5 , wherein the lipids are a combination of one or more ...

Подробнее
Номер записи: 22
28-01-2016 дата публикации

Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients

Номер: US20160025751A1
Автор: Kim Ekroos, Reijo Laaksonen, Reini Hurme, Riika Katainen
Принадлежит: Zora Biosciences Oy

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Подробнее
Номер записи: 23
25-01-2018 дата публикации

PREDICTIVE MARKERS OF IBD

Номер: US20180024149A1
Автор: Benyacoub Jalil, Brahmbhatt Viral, Martin Francois-Pierre, Montoliu Roura Ivan, Rezzi Serge Andre Dominique, Schiffrin Eduardo
Принадлежит:

The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof. 1. An ex vivo analytical method of determining whether a subject has inflammatory bowel disease (IBD) , comprising:providing an isolated biological sample;measuring the concentration of at least two biomarkers in the sample;wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease,wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof.2. The method of wherein the concentration of the biomarkers in the sample significantly lower than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease.3. The method of comprising a phosphatidylcholine selected from the group consisting of monoacylphosphatidylcholine claim 1 , diacylphosphatidylcholine claim 1 , and alkylacylphosphatidylcholine.4. The method of claim 1 , wherein at least the concentration of 3 of 5 biomarkers is measured.5. The method of claim 1 , for predicting a relapse of IBD.6. The method of claim 1 , wherein a concentration of the biomarker in the sample of the subject that is significantly lower than a reference value for the biomarker indicates that the subject has increased risk of having an IBD relapse.7. The method of claim 1 , wherein at least one further biomarker is selected from the group of amino acids consisting of arginine claim 1 , glycine claim 1 , ...

Подробнее
Номер записи: 24
29-01-2015 дата публикации

Means and methods for assessing neuronal toxicity

Номер: US20150031572A1
Автор: Alexandre Prokoudine, Bennard Van Ravenzwaay, Eric Fabian, Hennicke Kamp, Jan C. Wiemer, Michael Manfred Herold, Ralf Looser, Tilmann B. Walk, Volker Strauss, Werner Mellert
Принадлежит: BASF SE

The present invention pertains to the field of diagnostics for neuronal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing neuronal toxicity. It also relates to a method for determining whether a compound is capable of inducing such neuronal toxicity in a subject and to a method of identifying a drug for treating neuronal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing neuronal toxicity.

Подробнее
Номер записи: 25
02-02-2017 дата публикации

MARKER OF NEUROPATHIC GAUCHER'S DISEASE AND METHODS OF USE THEREOF

Номер: US20170030926A1
Автор: Futerman Anthony, Zigdon Hila
Принадлежит:

A biomarker of the neuronopathic types of Gaucher's disease (nGD) is provided, and use thereof for assisting the diagnosis of this form of the disease and its severity. In particular, use of the level of trans-membrane glycoprotein non-metastatic B (GPNMB) or a fragment thereof in the cerebrospinal fluid (CSF) as a diagnostic marker of nGD is provided. Further provided are methods for selecting drugs and assessing the efficacy of drugs and therapies for treating nGD. 1. A method for assessing the responsiveness of a subject diagnosed with neuronopathic Gaucher's disease (nGD) to a treatment , the method comprising:(a) measuring a level of GPNMB or a fragment thereof in a first cerebrospinal fluid (CSF) sample obtained from the subject;(b) administering the treatment to said subject;(c) measuring a level of GPNMB or the fragment thereof in a second CSF sample obtained from said subject at a selected time period after the treatment was administered; and(d) calculating a ratio of the level of GPNMB or the fragment thereof in the first CSF sample to the level of GPNMB or the fragment thereof in the second CSF sample;wherein a ratio of greater than 1 identifies said subject as responsive to said treatment.2. The method of claim 1 , wherein GPNMB has an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.3. The method of claim 1 , wherein the fragment of GPNMB is derived from the extracellular domain of GPNMB.4. The method of claim 1 , wherein measuring a level of GPNMB or a fragment thereof is performed using an immunologic technique.5. The method of claim 4 , wherein the immunologic technique is selected from the group consisting of fluorescence immunoassay (FIA) method claim 4 , an enzyme immunoassay (EIA) method claim 4 , a radioimmunoas say (RIA) method claim 4 , a Western blotting method and slot blot.6. The method of claim 1 , wherein the method further comprises repeating steps (c) and (d) at least once claim 1 , wherein a third ...

Подробнее
Номер записи: 26
02-02-2017 дата публикации

METHOD FOR MEASURING CLOTTING TIME, MEASUREMENT DEVICE FOR CLOTTING TIME, AND REAGENT KIT

Номер: US20170030933A1
Автор: IEKO Masahiro, KUMANO Osamu, Suzuki Takeshi, YAMAGUCHI Haruki
Принадлежит:

Disclosed is a method for measuring a clotting time, including: 1. A method for measuring a clotting time , comprising:a mixing step of mixing a blood sample, an activator, a phospholipid, and a manganese ion-forming compound to obtain a specimen; anda measurement step of mixing the specimen obtained in the mixing step with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen,wherein the blood sample is mixed with the manganese ion-forming compound separately from the activator and the phospholipid in the mixing step.2. The method according to claim 1 , wherein the mixing step includes the steps of:(A) mixing the blood sample, the activator, and the phospholipid to obtain a mixture; and(B) mixing the mixture with the manganese ion-forming compound.3. The method according to claim 2 , wherein the manganese ion-forming compound is mixed with the mixture in step (B) within 150 seconds after end of mixing the blood sample claim 2 , the activator claim 2 , and the phospholipid in step (A).4. The method according to claim 1 , wherein the manganese ion-forming compound in the measurement specimen has a final concentration of 0.1 μM or more and less than 10 mM.5. The method according to claim 1 , wherein the manganese ion-forming compound in the measurement specimen has a final concentration of 0.1 mM or more and less than 5 mM.6. The method according to claim 1 , wherein claim 1 , in the measurement step claim 1 , the measurement specimen is incubated at a temperature of 30° C. or more and 45° C. or less claim 1 , and then the calcium salt is mixed with the measurement specimen.7. The method according to claim 1 , wherein claim 1 , in the measurement step claim 1 , the measurement specimen is incubated at a temperature of 36° C. or more and 38° C. or less claim 1 , and then the calcium salt is mixed with the measurement specimen.8. The method according to claim 1 , wherein claim 1 , in the measurement step claim 1 , ...

Подробнее
Номер записи: 27
02-02-2017 дата публикации

USE OF LIPID PARTICLES IN MEDICAL DIAGNOSTICS

Номер: US20170030935A9
Автор: Bowen Benjamin P., LOUIE Katherine B., NORTHEN Trent R.
Принадлежит:

Disclosed herein are methods for identifying one or more diseased cells in a subject, methods for cancer diagnosis, methods for determining cancer progression in a subject and methods for assessing health status in a subject. 1. A method for identifying one or more diseased cells in a subject , comprising:(a) providing a biological sample derived from a subject;(b) analyzing the biological sample by mass spectrometry; and(c) determining the abundance of one or more lipids in the biological sample, wherein an altered abundance of the one or more lipids in the biological sample, as compared to a reference level, indicates a presence of one or more diseased cells in the subject from which the biological sample is derived.2. The method of claim 1 , wherein the reference level is established using a reference sample from a healthy subject.3. (canceled)4. (canceled)5. The method of claim 1 , wherein the biological sample comprises a tissue sample claim 1 , a bodily fluid claim 1 , a cell culture or extracts thereof claim 1 , or a combination thereof.6. (canceled)7. (canceled)8. The method of claim 1 , wherein the biological sample comprises one or more lipid-containing microparticles.9. The method of claim 8 , wherein the one or more lipid-containing microparticles are exosomes claim 8 , cell membrane fragments claim 8 , cellular and intracellular organelle fragments claim 8 , lipid bilayers claim 8 , or a combination thereof.10. (canceled)11. (canceled)12. The method of claim 8 , wherein analyzing the biological sample by mass spectrometry comprises isolating the one or more lipid-containing microparticles from the biological sample and analyzing the lipid-containing microparticles by mass spectrometry.13. The method of claim 12 , wherein the isolating step comprises isolating the one or more lipid-containing microparticles from the biological sample by filtration claim 12 , centrifugation claim 12 , microfluidics claim 12 , antibody affinity capture claim 12 , or a ...

Подробнее
Номер записи: 28
01-02-2018 дата публикации

PHOSPHATIDYLETHANOLAMINE-SPECIFIC PROBES

Номер: US20180031583A1
Автор: Hou Songwang, Zhao Ming
Принадлежит:

Provided herein are phosphatidylethanolamine (PE)-specific probes and methods of use thereof. In particular, the present invention provides conjugates of PE binding moieties with detectable markers, and methods of use thereof to detect and/or characterize PE within cells. 1. A composition comprising a conjugate of a phosphatidylethanolamine-binding moiety (PE-binding moiety) and a detectable moiety.2. The composition of claim 1 , wherein the PE-binding moiety has at least 70% sequence identity with duramycin and is capable of stably binding phosphatidylethanolamine (PE).3. The composition of claim 2 , wherein said PE-binding moiety comprises duramycin.4. The composition of claim 1 , wherein said detectable moiety is selected from the list consisting of: a radiolabel claim 1 , a hapten claim 1 , a binding moiety claim 1 , a fluorescent moiety claim 1 , a chromophore claim 1 , a mass tag claim 1 , a contrast agent claim 1 , a spin label claim 1 , a handle claim 1 , and a surface.5. The composition of claim 1 , wherein said detectable moiety comprises a fluorescent moiety.6. The composition of claim 5 , wherein said detectable moiety comprises a fluorescent protein.7. The composition of claim 6 , wherein said detectable moiety comprises enhanced green fluorescent protein (EGFP).8. The composition of claim 1 , wherein the detectable moiety and the PE-binding agent are connected by a linker moiety.9. The composition of claim 8 , wherein said linker moiety is a PEG linker or a peptide linker.10. The composition of claim 1 , further comprising a functional moiety.11. The composition of claims 10 , wherein the functional moiety is a localization signal.12. The composition of claims 11 , wherein the localization signal is Tat peptide.13. The composition of claim 1 , wherein said conjugate is nontoxic to cells.14. The composition of claim 1 , wherein said conjugate is cell permeable.15. A composition comprising a conjugate of:(a) duramycin; and(b) enhanced green fluorescent ...

Подробнее
Номер записи: 29
01-02-2018 дата публикации

METHODS OF DETECTING ANALYTES AND DIAGNOSING TUBERCULOSIS

Номер: US20180031584A1
Автор: CRAWFORD Alexis C., GRANGER Jennifer H., LAURENTIUS Lars Bjorn, PORTER Marc D.
Принадлежит:

A method for detecting lipoarabinomannan in a biological sample is described, including the step of contacting the biological sample with at least one acid selected from the group consisting of perchloric acid, trifluoroacetic acid, and sulfosalicylic acid. Methods for diagnosing diseases, including tuberculosis, and kits for the described methods are also presented. 1. A method for detecting lipoarabinomannan in a biological sample , the method comprising contacting the biological sample with an acid selected from the group consisting of perchloric acid , trifluoroacetic acid , and sulfosalicylic acid.2. The method of claim 1 , further comprising removing protein precipitate from the biological sample after contacting the biological sample with the acid.3. The method of claim 2 , wherein the protein precipitate is removed by centrifugation.4. The method of claim 2 , further comprising determining the lipoarabinomannan concentration in the biological sample after removing the protein precipitate.5. The method of claim 4 , wherein the lipoarabinomannan concentration is determined using at least one of ELISA; a surface-enhanced Raman scattering (SERS)-based immunoassay; an assay using detection via fluorescence claim 4 , diffuse reflectance claim 4 , mass spectrometric claim 4 , liquid or gas chromatographic spectroscopies; a magnetic claim 4 , colorometric or electrochemical response; a lateral or vertical flow assay; and surface plasmon resonance.6. The method of claim 1 , wherein the biological sample comprises a serum of a mammal.7. The method of claim 1 , wherein the method is capable of detecting lipoarabinomannan in the biological sample at concentrations of from about 0.01 to about 10 claim 1 ,000 ng/mL.8. A kit for detecting lipoarabinomannan in a biological sample using the method of claim 1 , the kit comprising an acid selected from the group consisting of perchloric acid claim 1 , trifluoroacetic acid claim 1 , and sulfosalicylic acid claim 1 , and further ...

Подробнее
Номер записи: 30
31-01-2019 дата публикации

Methods and systems for detecting melanoma

Номер: US20190033313A1
Автор: Candice Z. Ulmer, Christiana M. Shaw, Louis Searcy, Michael T. COSTANZO, Nikolaus Gravenstein, Rick Yost
Принадлежит: University of Florida Research Foundation Inc

The present disclosure provides methods and systems for detecting melanoma in a host. The methods include non-invasive methods of detecting melanoma and methods and systems for providing a molecular signature and/or melanoma biomarker signature for a host.

Подробнее
Номер записи: 31
01-05-2014 дата публикации

Diabetes panel

Номер: US20140120559A1
Автор: Ernst J. Schaefer
Принадлежит: Boston Heart Diagnostics Corp

The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if the level exceeds a predetermined threshold.

Подробнее
Номер записи: 32
04-02-2021 дата публикации

SERUM-BASED BIOMARKERS OF PANCREATIC CANCER AND USES THEREOF FOR DISEASE DETECTION AND DIAGNOSIS

Номер: US20210033614A1
Автор: Pastural Elodie, Ritchie Shawn
Принадлежит:

Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described. 2. The method of claim 1 , wherein the mass spectrometer is equipped with a chromatographic system.3. (canceled)4. The method of claim 1 , wherein the sample is a blood serum sample.56-. (canceled)7. The method of claim 1 , wherein a liquid/liquid extraction is performed on the blood sample whereby non-polar metabolites are dissolved in an organic solvent and polar metabolites are dissolved in an aqueous solvent.8. The method of claim 7 , wherein the extracted samples are analyzed by: positive or negative electrospray ionization claim 7 , positive or negative atmospheric pressure chemical ionization or claim 7 , and combinations thereof; by MS/MS transition; or by extracted ion current (EIC) chromatography and MS/MS transition.9. (canceled)10. The method of claim 1 , wherein said one or more than one reference blood sample is from one or more pancreatic cancer-negative humans.1218-. (canceled)19. The method of claim 1 , wherein the molecule is:a lysophosphatidylcholine (LysoPC) selected from the group consisting of LysoPC 14:1, LysoPC 16:0, LysoPC 16:1, LysoPC 16:2, LysoPC 18:0, LysoPC 18:1, LysoPC 18:2, LysoPC 18:3, LysoPC 20:1, LysoPC 20:2, LysoPC 20:3, LysoPC 20:4, LysoPC 20:5, LysoPC 20:6, LysoPC 22:3, LysoPC 22:4, LysoPC 22:5, LysoPC 22:6, LysoPC 24 ...

Подробнее
Номер записи: 33
08-02-2018 дата публикации

DIAGNOSTIC METHOD FOR PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME (PANS) AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCI INFECTION (PANDAS)

Номер: US20180038870A1
Автор: Cunningham Phina Madeleine, Kirvan Christine, Shimasaki Craig David, Swedo Susan E.
Принадлежит:

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined. 1. (canceled)2. A method of analyzing a sample from a patient , comprising:a) providing a surface comprising at least four molecules selected from lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, human serotonin receptor 5HT2A, and human serotonin receptor 5HT2C, wherein the at least four molecules are immobilized on the surface;b) contacting the surface with the sample to form at least four antibody/molecule complexes on the surface, the at least four antibody/molecule complexes selected from anti-lysoganglioside antibody/lysoganglioside complex, anti-tubulin antibody/tubulin complex, anti-dopamine receptor D1 antibody/dopamine receptor D1 complex, anti-dopamine receptor D2 antibody/dopamine receptor D2 complex, anti-human serotonin receptor 5HT2A antibody/human serotonin receptor 5HT2A complex, and anti-human serotonin receptor 5HT2C antibody/ ...

Подробнее
Номер записи: 34
08-02-2018 дата публикации

CARDIOVASCULAR DISEASE RISK ASSESSMENT

Номер: US20180038877A1
Автор: Schaefer Ernst J.
Принадлежит:

The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers LDL and HDL subfractions, along with Lp(a) provides significant improvement in predicting CVD versus standard assays that include standard risk factors. Methods of the invention comprise measuring LDL and HDL subfractions in addition to Lp(a) without reference to standard risk factor measurements, such as CRP, total cholesterol, body mass index, weight, triglycerides, and the like. It is unexpected that an algorithm focusing only on LDL and HDL subfractions and Lp(a) would be more informative as to CVD risk than measurements that are much more comprehensive in terms of the markers that are reviewed. In particular, the sdLDL-C subfraction of LDL and the ApoA-1 in large alpha-1 HDL are most informative in conjunction with Lp(a). 1. A method for assessing cardiovascular risk , the method comprising the steps of:obtaining a sample from a patient;conducting an assay on the sample to determine blood levels of an LDL subfraction, an HDL subfraction, and Lp(a);entering said levels into a multivariate model to produce a probability of the individual developing cardiovascular disease.2. The method of claim 1 , further comprising:obtaining information about one or more of the patient's age, history of blood pressure treatment, smoking, and diabetes; andentering the obtained information into the multivariate model.3. The method of claim 1 , wherein the multivariate model does not include a C-Reactive protein level.4. The method of claim 1 , wherein the multivariate model does not include triglycerides claim 1 , total cholesterol claim 1 , body mass index claim 1 , waist circumference claim 1 , patient use of cholesterol lowering medication claim 1 , and patient use of glucose lowering medication.5. The method of claim 1 , wherein the assay comprises one selected from a group consisting of an enzymatic assay claim 1 , high-performance liquid ...

Подробнее
Номер записи: 35
12-02-2015 дата публикации

sPLA2 MONITORING STRIP

Номер: US20150044714A1
Автор: Cunningham Timothy J., Kollins Callaghan Katherine Marie, Yao Lihua
Принадлежит: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine

A device and method for determining the presence or absence, or the level of, sPLA2 activity in a fluid sample. The device includes an absorbent matrix that defines a flow path for a fluid sample, a first region of the absorbent matrix for applying a fluid sample, where one of the components selected from a bioactive sPLA2 substrate and a label is dried onto or within the first region of the absorbent matrix, a second region of the absorbent matrix downstream of, and in fluid communication with, the first region for detecting an aggregated reaction product, where the other component not present in the first region is dried onto or within the second region of the absorbent matrix. 1. A device for detecting the presence or absence of sPLA2 in a fluid sample , comprising:an absorbent matrix that defines a flow path for a fluid sample;a first region of the absorbent matrix for applying a fluid sample, wherein one of the components selected from a bioactive sPLA2 substrate and a label is dried onto or within the first region of the absorbent matrix; and wherein in the absence of sPLA2 in the fluid sample, applying the fluid sample does not result in a recognizable aggregated reaction product in the second region; and', 'wherein in the presence of sPLA2 in the fluid sample, applying the fluid sample results in a detectable aggregated reaction product in the second region., 'a second region of the absorbent matrix downstream of, and in fluid communication with, the first region for detecting an aggregated reaction product, wherein the other component not present in the first region is dried onto or within the second region of the absorbent matrix;'}2. The device of claim 1 , wherein the label comprises a gold sol.3. The device of claim 2 , wherein the gold sol comprises streptavidin coated gold particles.4. The device of claim 1 , wherein the bioactive sPLA2 substrate is Diheptanoyl Thio-PC.5. The device of claim 3 , further comprising a linker molecule dried onto or ...

Подробнее
Номер записи: 36
18-02-2016 дата публикации

METHODS FOR DETERMINING THE RISK OF CARDIOVASCULAR DISEASE IN A SUBJECT HAVING A CHRONIC VIRAL INFECTION

Номер: US20160045494A1
Автор: Chance Mark R.
Принадлежит:

A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) in the subject and comparing the determined level of ENPP2 to a control level, wherein an increased level of ENPP2 is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection. 1. A method of determining the risk of cardiovascular disease in a subject having a chronic viral infection , the method comprising:determining a level of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) in the subject;comparing the determined level of ENPP2 to a control level, wherein an increased level of ENPP2 is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection.2. The method of claim 1 , further comprising the step of obtaining one or more biological samples from the subject claim 1 , the bodily samples including ENPP2.3. The method of claim 1 , the cardiovascular disease resulting from chronic immune activation (CIA) mediated by chronic viral infection.4. The method of claim 2 , the one or more biological samples comprising blood serum or plasma.5. The method of claim 1 , wherein the level of the level of ENPP2 is determined using an ELISA assay.6. The method of claim 1 , the control level comprising the level of ENPP2 in a population of subjects having a chronic viral infection but not having cardiovascular disease associated with the chronic viral infection.7. The method of claim 1 , wherein the cardiovascular disease is selected from the group consisting of myocardial infarction claim 1 , coronary artery disease claim 1 , angina claim 1 , atherosclerosis claim 1 , aneurysm claim 1 , congestive heart failure claim 1 , left ventricular dysfunction claim 1 , and cerebrovascular disease.8. The method of claim 1 , the chronic viral infection selected from ...

Подробнее
Номер записи: 37
18-02-2016 дата публикации

COMPOSITIONS OF MATTER THAT REDUCE PAIN, SHOCK, AND INFLAMMATION BY BLOCKING LINOLEIC ACID METABOLITES AND USES THEREOF

Номер: US20160045610A1
Автор: Bruno John Gordon, Hargreaves Kenneth Michael
Принадлежит:

A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs. 1. A compound comprising an aptamer having the structure 5′-ATA CGG GAG CCA ACA CCA CCG AAT GTG CTG CAG GAC TAA TCT GGA TGG CCA TGC AGA GCA GGT GTG ACG GAT-3′ (SEQ ID NO. 84)2. The compound of claim 1 , further comprising a compound that improves binding to plasma proteins claim 1 , delivery to inflamed tissue and/or exerts intrinsic pharmacodynamic properties coupled to the aptamer (SEQ ID NO. 84).3. The compound of claim 1 , further comprising a nonsteroidal anti-inflammatory drug coupled to the aptamer (SEQ ID NO. 84).4. The compound of claim 1 , further comprising a steroid coupled to the aptamer (SEQ ID NO. 84).5. The compound of claim 1 , further comprising an antihistamine coupled to the aptamer (SEQ ID NO. 84).6. The compound of claim 1 , further comprising a polyethylene glycol coupled to the aptamer (SEQ ID NO. 84).7. A compound comprising an aptamer having the structure 5′-ATC CGT CAC ACC TGC TCT GGG GGG GGA AGC TCG TGG TAT AAG GGG CGT TGA GGT GGT GTT GGC TCC CGT AT-3′ (SEQ ID NO. 67)8. The compound of claim 7 , further comprising a compound that improves binding to plasma proteins claim 7 , delivery to inflamed tissue and/or exerts intrinsic pharmacodynamic properties coupled to the aptamer ...

Подробнее
Номер записи: 38
15-02-2018 дата публикации

Physically Guided Rapid Evaporative Ionisation Mass Spectrometry ("REIMS")

Номер: US20180042582A1
Автор: Daniel Simon, Daniel Szalay, Emrys Jones, James Ian Langridge, Julia BALOG, Keith Richardson, Lajos Godorhazy, Michael Raymond MORRIS, Steven Derek Pringle, Zoltan Takats
Принадлежит: Micromass UK Ltd

A method is disclosed comprising obtaining physical or other non-mass spectrometric data from one or more regions of a target using a probe. The physical or other non-mass spectrometric data may be used to determine one or more regions of interest of the target. An ambient ionisation ion source may then used to generate an aerosol, smoke or vapour from one or more regions of the target.

Подробнее
Номер записи: 39
18-02-2016 дата публикации

Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample

Номер: US20160047829A1
Автор: Fischer Jenny, Frey Nobert, Fuhrmann Jens, Katus Hugo A, Reszka Regina, Sigl Johanna, Weis Tanja
Принадлежит:

The present invention relates to a method for determining a clearance normalized amount of a metabolite disease biomarker in a sample including the steps of (a) determining the amount of the disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease, (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample, and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b). Moreover, the invention also relates to a method for diagnosing a disease in a subject suspected to suffer therefrom and to a device for determining a clearance normalized amount of a metabolite disease biomarker in a sample. 114-. (canceled)15. A method for determining a clearance normalized amount of a metabolite disease biomarker in a sample comprising the steps of:(a) determining the amount of the metabolite disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease;(b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample; and(c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b),wherein said sample is blood or a derivative thereof.16. The method of claim 15 , wherein said kidney function biomarker is selected from the group consisting of cystatin C.17. The method of claim 15 , wherein said metabolite disease biomarker is a biomarker for cardiovascular diseases or disorders claim 15 , diabetes or metabolic syndrome or neurodegenerative diseases.18. The ...

Подробнее
Номер записи: 40
16-02-2017 дата публикации

METHODS FOR IMPROVING FERTILITY AND SELECTIVITY FOR DESIRED OFFSPRING SEX IN ARTIFICIAL INSEMINATION

Номер: US20170045500A1
Автор: Cohen Barb A.
Принадлежит:

A method for providing semen optimized for use in artificial insemination is described. Methods involve monitoring sperm cell metabolism by assays that produce results in real time, while sperm are still being processed into doses for use in insemination. Processing is modified in response to assay results, to optimize sperm performance. 3. The method of or , wherein said desired trait is selected from the group consisting of female gender bias in said sperm , male gender bias , fertility , and a combination thereof.4. The method of or , wherein said marker is selected from the group consisting of acrosome length , acrosome morphology , acrosome ruffling , expression of a cell surface molecule , electrostatic charge of said sperm , and permeability of sperm membrane(s) , a lipid , cholesterol , phosphatidylserine , a sugar and a protein , an intracellular ion , calcium ion , bicarbonate.5. The method of or , wherein said sample is assayed for said marker at intervals ranging from 5 minutes up to and including 8 hours.6. The method of the or , wherein said marker is selected from the group consisting of a cell surface ligand , an enzyme and a receptor.7. The method of or , wherein said marker is a cell surface marker , and wherein said jump point occurs when expression of said marker in said sample has decreased from its maximal expression by a percentage ranging from 95% to 25% as determined by the assay of step ii).82. The method of or , wherein said marker is a cell surface marker , and wherein said jump point occurs when the expression of said marker in said sample has increased from its minimal expression by a percentage increase ranging from 5% to 1000% as determined by the assay of step .9. The method of or , wherein said desired trait is an excess of active , fertile female sperm relative to active , fertile male sperm in said sample.10. The method of or , wherein said desired trait is an excess of active , fertile male sperm relative to active , fertile ...

Подробнее
Номер записи: 41
15-02-2018 дата публикации

Rapid Evaporative Ionisation Mass Spectrometry ("REIMS") and Desorption Electrospray Ionisation Mass Spectrometry ("DESI-MS") Analysis of Swabs and Biopsy Samples

Номер: US20180047554A1
Автор: Daniel Simon, Daniel Szalay, Emrys Jones, James Ian Langridge, Julia BALOG, Keith Richardson, Lajos Godorhazy, Michael Raymond MORRIS, Steven Derek Pringle, Tamas Karancsi, Zoltan Takats
Принадлежит: Micromass UK Ltd

A method is disclosed comprising providing a biological sample on a swab, directing a spray of charged droplets onto a surface of the swab in order to generate a plurality of analyte ions, and analysing the analyte ions.

Подробнее
Номер записи: 42
25-02-2021 дата публикации

METHOD AND ASSOCIATED DEVICE FOR RAPID DETECTION OF TARGET BIOMOLECULES WITH ENHANCED SENSITIVITY

Номер: US20210055297A1
Автор: Bales Brian Christopher, Grossmann Gregory Andrew, Misner Matthew Jeremiah, Moore David Roger, Nelson John Richard, Olsen Cathryn Ellen, Smigelski Paul Michael
Принадлежит:

A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided. 1. A method for rapid diagnostic testing of a source biological sample comprising tuberculosis-lipoarabinomannan (TB-LAM) , comprising: diluting the source biological sample by at least 2× compared to the source urine sample to form a diluted biological sample;', 'contacting the diluted biological sample to an anion-exchange medium to capture the TB-LAM of the diluted biological sample;', 'capturing the TB-LAM of the diluted biological sample by the anion-exchange medium; and', 'eluting the captured-TB-LAM from the anion-exchange medium as a concentrated form of TB-LAM in an eluate under a salt concentration of at least 1M, wherein a concentration of the TB-LAM in the eluate is in a range from about 2× to 25× compared to a concentration of the TB-LAM in the diluted biological sample; and, 'concentrating the TB-LAM byloading the eluate comprising the concentrated form of the TB-LAM to a rapid diagnostic testing device comprising a TB-LAM-specific antibody for binding the concentrated form of the TB-LAM,wherein the eluate is loaded without any dilution, and wherein the TB-LAM binds to the TB-LAM-specific ...

Подробнее
Номер записи: 43
10-03-2022 дата публикации

METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS AND PREDICTION OF CLINICAL SENSITIVITY TO TREATMENT OF BILE ACID-RELATED DISORDERS

Номер: US20220072099A1
Автор: DEPAOLI Alexander Mark, LUO Jian, Tian Hui
Принадлежит:

Provided herein are methods of using 7α-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). 178-. (canceled)80. The method of claim 79 , wherein the peptide has an amino acid sequence consisting of SEQ ID NO:141.81. The method of claim 79 , further comprising obtaining the reference level of C4 in a control sample prior to administration of the peptide claim 79 , and wherein the control sample is from the same source as the test sample.82. The method of claim 79 , further comprising obtaining the reference level of C4 in a control sample from a control subject having the bile-acid related disorder.83. The method of claim 79 , wherein the level of C4 in the test sample obtained after administration with the peptide decreases 10% to 90% as compared to the reference level of C4.84. The method of claim 79 , wherein the level of C4 in the test sample obtained after administration with the peptide decreases 30% to 90% as compared to the reference level of C4.85. The method of claim 79 , wherein the level of C4 in the test sample obtained after administration with the peptide decreases 60% to 90% as compared to the reference level of C4.86. The method of claim 79 , wherein the determining the level of C4 in the test sample utilizes liquid chromatography-tandem mass spectrometry (LCMS/MS). This application is a continuation of U.S. Ser. No. 16/562,150, filed Sep. 5, 2019, which is a division of U.S. Ser. No. 15/524,896, filed May 5, 2017, now U.S. Pat. No. 10,434,144, which is a 371 national stage application of international application Serial No. PCT/ ...

Подробнее
Номер записи: 44
15-05-2014 дата публикации

Systems and apparatus for indicating risk of coronary stenosis

Номер: US20140134654A1
Автор: Chadwick D. Miller, Lawrence L. Rudel, Michael J. Thomas
Принадлежит: Wake Forest University Health Sciences

A computer-based method for determining a prediction of risk and/or an indication of extent of coronary stenosis in a human subject, comprises the steps of: (a) inputting the level of at least one cholesteryl ester measured in a blood sample collected from said subject; and then (b) inputting the age and gender of said subject; and then (c) generating in said computer from said cholesteryl ester level input, said age input and said gender input a prediction of risk and/or an indication of extent of coronary stenosis blood sample by mass spectrometry.

Подробнее
Номер записи: 45
01-03-2018 дата публикации

Spectrometric Analysis of Microbes

Номер: US20180057852A1
Автор: BALOG Julia, BOLT Frances, GODORHAZY Lajos, JONES Emrys, KARANCSI Tamás, Pringle Steven Derek, Richardson Keith, Simon Daniel, SZALAY Daniel, Takáts Zoltán
Принадлежит:

A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed. The method comprises: using a first device to generate smoke, aerosol or vapour from a target comprising or consisting of a microbial population; mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and analysing said spectrometric data in order to analyse said microbial population. 1. A method of analysis using mass spectrometry and/or ion mobility spectrometry comprising:automatically sampling a target comprising or consisting of a microbial population using a first device to generate smoke, aerosol or vapour from said target;adding a matrix to said aerosol, smoke or vapour;causing said aerosol, smoke or vapour, or analyte therein, to impact upon a collision surface located within a vacuum chamber of a spectrometer so as to generate a plurality of analyte ions;mass analysing and/or ion mobility analysing said analyte ions in order to obtain spectrometric data; andanalysing said spectrometric data in order to analyse said microbial population.2215-. (canceled)216. The method as claimed in claim 1 , wherein said step of using said first device to generate aerosol claim 1 , smoke or vapour from said target further comprises irradiating said target with a laser.217. The method as claimed in claim 1 , wherein said method comprises a high-throughput screening method.218. The method as claimed in claim 1 , wherein said method is used for drug discovery and/or drug analysis.219. The method as claimed in claim 1 , wherein said matrix is selected from the group consisting of: (i) a solvent for said aerosol claim 1 , smoke or vapour or analyte therein; (ii) an organic solvent; (iii) a volatile compound; (iv) polar molecules; (v) water; (vi) one or more alcohols; (vii) methanol; (viii) ethanol; (ix) isopropanol; (x) acetone; (xi) acetonitrile; (xii) 1-butanol; (xiii) tetrahydrofuran; (xiv) ethyl ...

Подробнее
Номер записи: 46
05-03-2015 дата публикации

Biomarkers for Bladder Cancer and Methods Using the Same

Номер: US20150065366A1
Автор: McDunn Jonathan E., Neri Bruce, PERICHON Regis, Wittmann Bryan
Принадлежит:

Methods for identifying and evaluating biochemical entities useful as biomarkers for bladder cancer, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for bladder cancer. 136-. (canceled)37. A method of determining or aiding in determining whether a subject has bladder cancer , comprising:analyzing a biological sample from a subject to determine the level(s) of one or more biomarkers for bladder cancer in the sample, wherein the one or more biomarkers are selected from Tables 1, 5, 7, 9, 11 and/or 13, andcomparing the level(s) of the one or more biomarkers in the sample to bladder cancer-positive and/or bladder cancer-negative reference levels of the one or more biomarkers in order to determine whether the subject has bladder cancer.38. The method of claim 37 , wherein the sample is analyzed using one or more techniques selected from the group consisting of mass spectrometry claim 37 , ELISA claim 37 , and antibody linkage.39. The method of claim 38 , wherein the method further comprises using a mathematical model comprising the one or more biomarkers to determine or aid in determining whether the subject has bladder cancer.40. The method of claim 37 , wherein the one or more biomarkers are selected from the group consisting of choline phosphate claim 37 , palmitoyl sphingomyelin claim 37 , adipate claim 37 , xanthurenate claim 37 , acetylcarnitine claim 37 , tyramine claim 37 , succinate claim 37 , adenosine claim 37 , 2-hydroxybutyrate (AHB) claim 37 , gulono 1 claim 37 ,4-lactone claim 37 , 2-methylbutyrylglycine claim 37 , arachidonate claim 37 , glutamate claim 37 , guanidinoacetate claim 37 , gamma-aminobutyrate (GABA) claim 37 , valine claim 37 , spermine claim 37 , proline claim 37 , leucine claim 37 , isoleucine claim 37 , 3-hydroxybutyrate (BHBA) claim 37 , anserine claim 37 , pyridoxate claim 37 , 1 claim 37 ,2-propanediol claim 37 , kynurenine claim 37 , ...

Подробнее
Номер записи: 47
20-02-2020 дата публикации

Liquid Trap or Separator for Electrosurgical Applications

Номер: US20200058478A1
Автор: BALOG Julia, GODORHAZY Lajos, KARANCSI Tamás, Pringle Steven Derek, Simon Daniel, SZALAY Daniel, Takáts Zoltán
Принадлежит:

An apparatus for mass spectrometry and/or ion mobility spectrometry is disclosed comprising a first device arranged and adapted to generate aerosol, smoke or vapour from a target and one or more second devices arranged and adapted to aspirate aerosol, smoke, vapour and/or liquid to or towards an analyser. A liquid trap or separator is provided to capture and/or discard liquid aspirated by the one or more second devices. 1. Apparatus for mass spectrometry and/or ion mobility spectrometry comprising:a first device arranged and adapted to generate aerosol, smoke or vapour from a target;a mass and/or ion mobility analyser;one or more second devices arranged and adapted to aspirate aerosol, smoke or vapour and/or liquid to or towards the analyser; anda liquid trap or separator located between said first device and said mass and/or ion mobility analyser, wherein said liquid trap or separator is arranged and adapted to capture and/or discard liquid aspirated by said one or more second devices.28-. (canceled)9. Apparatus as claimed in claim 1 , wherein said first device comprises one or more electrodes claim 1 , and wherein said first device is arranged and adapted to generate said aerosol claim 1 , smoke or vapour from said target by contacting said target with said one or more electrodes.10. Apparatus as claimed in claim 9 , wherein said one or more electrodes comprises either: (i) a monopolar device claim 9 , wherein said apparatus optionally further comprises a separate return electrode; (ii) a bipolar device; or (iii) a multi-phase RF device claim 9 , wherein said apparatus optionally further comprises a separate return electrode or electrodes.11. (canceled)12. Apparatus as claimed in claim 9 , further comprising a device arranged and adapted to apply an AC or RF voltage to said one or more electrodes in order to generate said aerosol claim 9 , smoke or vapour.13. (canceled)14. (canceled)15. Apparatus as claimed in claim 1 , whereinsaid first device comprises a laser ...

Подробнее
Номер записи: 48
17-03-2022 дата публикации

BIOCHEMICAL DIAGNOSTIC TEST FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Номер: US20220082576A1
Автор: HENRÍQUEZ Marcela, QUIROGA Sara, ROJAS Eric, SOLARI Sandra, VARGAS Sergio
Принадлежит:

The invention relates to a biochemical diagnostic test performed on peripheral blood, which allows the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Specifically, the serum levels of at least 6 markers corresponding to 2 groups of functional lipids, esfingolipids and long-chain polyunsaturated fatty acids (LC-PUFAs) are measured, specifically: Ceramide C16:0, Ceramide C24:0, Deoxy dihydro-ceramide C24:1 and Sphinganin 1-phosphate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), detecting a variation in concentrations with respect to the values for the control population. 2. Diagnostic method according to claim 1 , CHARACTERIZED in that there is a variation in the absolute values for Deoxy dihydro-ceramide C24:1 and Sphinganin 1-P and ratio Ceramide C24:0/Ceramide C16:0 (C24:0/C16:0) and DHA/EPA with respect to the normal values obtained in the healthy population control group.4. Diagnostic method according to claim 1 , CHARACTERIZED in that the score is calculated after applying a predictive model on the input variables (z-score) representing the variation of the absolute values for Deoxy dihydro-ceramide C24:1 and Sphinganin 1-P and ratio Ceramide C24:0/Ceramide C16:0 (C24:0/C16:0) and DHA/EPA with respect to the normal values obtained in the healthy population control group.5. Diagnostic method according to claim 1 , CHARACTERIZED in that in addition to the 6 lipids are optionally incorporated one or more of these 22 markers: sphingosine-1-phosphate claim 1 , ceramides C18:0 claim 1 , C20:0 claim 1 , C22:0 and C24:1; dihydroceramides C18 claim 1 , C18:1 claim 1 , C24:0 and C24:1; deoxy-ceramides C16:0 and C24:1 and deoxy-dihydroceramide C16:0; sphingomyelins (SM) SM C16:0 claim 1 , SM C18:0 claim 1 , SM C18:1 and SM C24:1 claim 1 , linoleic acid (LA) claim 1 , γ-linoleic acid (GLA) claim 1 , alpha-linolenic acid (ALA) claim 1 , dihomo-gamalinolenic acid (DGLA) claim 1 , arachidonic acid (AA) claim 1 , and docosapentanoic acid (DPA) ...

Подробнее
Номер записи: 49
11-03-2021 дата публикации

COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF

Номер: US20210069145A1
Автор: Braeckman Rene, Soni Paresh, Stirtan William
Принадлежит:

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides and a fatty acid desaturation index (“FADI”) associated with a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl , the method comprising determining a baseline FADI level associated with the subject; and thereafter administering to the subject a pharmaceutical composition comprising about 4 grams per day of ethyl eicosapentaenoate to effect a reduction in triglycerides and the FADI associated with the subject.2. The method of further comprising determining a baseline LDL-C level associated with the subject before administering the ethyl eicosapentaenoate claim 1 , wherein the baseline LDL-C level is about 40 mg/dl to about 115 mg/dl.3. The method of claim 2 , wherein the step of administering the pharmaceutical composition effects a reduction in serum LDL-C and/or fasting triglycerides.4. The method of claim 3 , wherein the step of administering the pharmaceutical composition effects at least a 5% reduction in LDL-C and/or fasting triglycerides.5. The method of claim 3 , wherein the step of administering the pharmaceutical composition effects at least a 10% or at least a 15% reduction in triglycerides.6. The method of claim 1 , wherein the step of administering the pharmaceutical composition effects a reduction in FADI of at least about 2% claim 1 , at least about 3% claim 1 , at least about 4% claim 1 , at least about 5% claim 1 , at least about 6% claim 1 , at least about 7% claim 1 , at least about 8% claim 1 , at least about 9% claim 1 , at least about 10% claim 1 , at least about 11% claim 1 , at least about 12% claim 1 , at least about 13% claim 1 , at least about 14% claim 1 , at least about 15% claim 1 , at least about 16% claim 1 , at least about 17% claim 1 , at least about 18% claim 1 , at least ...

Подробнее
Номер записи: 50
12-03-2015 дата публикации

9-OXO-HODE AS A BIOMARKER FOR HEALTHY AGING

Номер: US20150072043A1
Автор: Collino Sebastiano, Guy Philippe Alexandre, Martin Francois-Pierre, Rezzi Serge Andre Dominique, Roura Ivan Montoliu
Принадлежит:

Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-HODE as biomarker. 1. A method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders , comprising:obtaining a serum sample from a subjectdetermining the level of 9-Oxo-HODE, in the sample, andcomparing the subject's 9-Oxo-HODE level to a predetermined reference value,wherein the predetermined reference value is based on an average serum 9-Oxo-HODE level in a control population, andwherein a lower serum 9-Oxo-HODE level in the sample compared to the predetermined reference value indicates an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders.2. The method of claim 1 , further comprising:determining the level of at least one of SM-OH 22:1, SM 24:0, PC-O 40:1, 9-HODE, LPC 18:0, PC-O 34:1, or LTE4 in the sample, andcomparing the subject's level of at least one of SM-OH 22:1, SM 24:0, PC-O 40:1, 9-HODE, LPC 18:0, PC-O 34:1, or LTE4 to a predetermined reference value,wherein the predetermined reference value is based on average serum SM-OH 22:1, SM 24:0, PC-O 40:1, 9-HODE, LPC 18:0, PC-O 34:1, or LTE4 level in a control population, andwherein a lower serum LPC 18:0 level in the sample and/or a lower serum SM-OH 22:1, SM 24:0, PC-O 40:1, 9-HODE, or LPC 18:0 level in the sample compared to the predetermined reference values indicate an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders, and/orwherein elevated serum PC-O 34:1 and/or LTE4 levels in the sample compared to the predetermined ...

Подробнее
Номер записи: 51
08-03-2018 дата публикации

Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients

Номер: US20180067138A1
Автор: Ekroos Kim, Hurme Reini, Katainen Riikka, Laaksonen Reijo
Принадлежит:

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. 126-. (canceled)30. The method of claim 27 , wherein(a) the one or more lipid-lipid concentration ratio(s) whose increase is compared to the control is selected from: Cer(d18:1/18:0)/PC 16:0/18:1, Cer(d18:1/24:1)/PC 16:0/18:1, Cer(d18:1/24:1)/PC 16:0/18:2, Cer(d18:1/18:0)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/18:1, Cer(d18:1/24:1)/PC 18:0/18:2, Cer(d18:1/18:0)/PC 18:1/18:1, Cer(d18:1/24:1)/PC 18:1/18:1, Cer(d18:1/24:1)/PC 18:1/18:2, Cer(d18:1/18:0)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 16:0/20:3, Cer(d18:1/24:1)/PC 18:0/20:3 and Cer(d18:1/24:1)/PC O-40:3;(b) the one or more lipid-lipid concentration ratio(s) whose decrease is compared to the control is selected from: PC 18:1/18:2/PS O-16:0/18:2-alkenyl, PC 18:1/18:2/PS O-16:1/18:2-alkyl, PC 16:0/20:3/PS O-16:0/18:2-alkenyl, PC 16:0/20:3/PS O-16:1/18:2-alkyl, PC 18:0/20:3/PS O-16:0/18:2-alkenyl, PC 18:0/20:3/PS O-16:1/18:2-alkyl, PC 18:0/20:3/PS O-18:2/16:0-alkenyl, PC 16:0/20:4/PS O-16:0/18:2-alkenyl, PC 16:0/20:4/PS O-16:1/18:2-alkyl, PC 18:0/20:4/PS O-16:0/18:2-alkenyl, PC 18:0/20:4/PS O-16:1/18:2-alkyl and PC O-40:3/PS O-18:2/16:0-alkenyl;(c) the one or more lipid-clinical concentration ratio(s) whose increase is compared to the control is selected from: Cer(d18:1/16:0)/total cholesterol, Cer(d18:1/18:0)/LDL cholesterol, PC O-32:0 ( ...

Подробнее
Номер записи: 52
12-03-2015 дата публикации

PC-O 40:1 AS A BIOMARKER FOR HEALTHY AGING

Номер: US20150072320A1
Автор: Collino Sebastiano, Guy Philippe Alexandre, Martin Francois-Pierre, Rezzi Serge Andre Dominique, Roura Ivan Montoliu
Принадлежит:

Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using PC—O 40:1 as biomarker. 1. A method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders , comprisingobtaining a serum sample from a subjectdetermining the level of PC—O 40:1, in the sample, andcomparing the subject's PC—O 40:1 level to a predetermined reference value,wherein the predetermined reference value is based on an average serum PC—O 40:1 level in a control population, andwherein a decreased serum PC—O 40:1 level in the sample compared to the predetermined reference value indicates an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders.2. The method of claim 1 , further comprisingdetermining the level of at least one of SM-OH 22:1, LPC 18:0, SM 24:0, PC—O 34:1, 9-HODE, 9-oxo-HODE, or LTE4 in the sample, andcomparing the subject's level of at least one of SM-OH 22:1, LPC 18:0, SM 24:0, PC—O 34:1, 9-HODE, 9-oxo-HODE, or LTE4 to a predetermined reference value,wherein the predetermined reference value is based on average serum SM-OH 22:1, LPC 18:0, SM 24:0, PC—O 34:1, 9-HODE, 9-oxo-HODE, or LTE4 level in a control population, andwherein a decrease serum PC—O 40:1 level in the sample and/or a lower serum SM-OH 22:1, LPC 18:0, SM 24:0, PC—O 40:1, 9-HODE, or 9-oxo-HODE level in the sample compared to the predetermined reference values indicate an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders, and/orwherein increased serum LTE4, PC—O 34:1 levels in the sample compared to the ...

Подробнее
Номер записи: 53
09-03-2017 дата публикации

COMPOSITIONS AND METHODS UTILIZING LYSOPHOSPHATIDYLCHOLINE SCAFFOLDS

Номер: US20170067919A1
Автор: Nguyen Nam Long, SILVER David Lawrence, Zahler Robert
Принадлежит:

The invention relates to compositions and methods for utilizing lysophosphatidylcholine scaffolds. The compositions and methods can be used for LPC-mediated delivery of fatty acids and other molecules; to screen and identify fatty acid formulations for parenteral nutrition; and for live animal organ imaging, among other uses. The invention also provides compositions and methods for utilizing mutations and polymorphisms in human Mfsd2a as markers for neurological deficits. 1. A method for screening one or more compound to determine transport via the Mfsd2a protein , the method comprising:(a) contacting a biological mixture comprising said one or more compound with a genetically modified mouse that comprises in its genome a homozygous disruption of the Mfsd2a gene (KO mouse) and a wild type mouse;(b) measuring the amount of said one or more compound in a tissue or fluid of the KO mouse and the wild type mouse; and(c) comparing the amount of said one or more compound in the tissue or fluid of the KO mouse and the wild-type mouse, wherein higher amounts of said one or more compound in the wild-type mouse as compared to the KO mouse is an indication of transport of the compound via Mfsd2a protein.2. The method of claim 1 , wherein the KO mouse does not express functional Mfsd2a protein; wherein the biological mixture is derived from milk claim 1 , fish oil extracts claim 1 , or LPC formulations; wherein the tissue or fluid is brain claim 1 , eye claim 1 , liver claim 1 , heart claim 1 , or breast milk; wherein the method of contacting is via oral or i.v. administration; wherein said one or more compound is a nutritional supplement claim 1 , and optionally wherein the nutritional supplement is a LPC formulation.37.-. (canceled)8. A method for screening one or more compound to determine transport via the Mfsd2a protein claim 1 , the method comprising:(a) contacting a biological mixture comprising said one or more compound with a cell line comprising a human wild type ...

Подробнее
Номер записи: 54
15-03-2018 дата публикации

ENRICHMENT OF LYSOPHOSPHATIDIC ACIDS WITH TEMPLATED POLYMERIC MATERIALS

Номер: US20180071716A1
Автор: Escobedo-Cordova Jorge O., Sibrian-Vazquez Martha, Strongin Robert M., Wang Jialu
Принадлежит: Portland State University

Embodiments of templated polymeric materials capable of binding lysophosphatidic acids (LPAs) are disclosed. Methods of making and using the templated polymeric materials also are disclosed. The disclosed templated polymeric materials are molecularly imprinted polymers that bind LPAs and facilitate the production of lysophosphatidic acid-enriched samples, for instance through extraction of lysophosphatidic acids from biological samples, such as plasma or serum samples. 130-. (canceled)31. A molecularly imprinted polymer , comprising: polymerizing the monomers in a solution comprising (i) a solvent, (ii) a guest molecule comprising an anionic head group and a hydrophobic tail portion comprising a single aliphatic or heteroaliphatic chain with a length of from 12-24 carbons, (iii) a crosslinker, and (iv) a radical polymerization initiator to produce a polymer containing the guest molecule, and', 'removing the guest molecule from the polymer containing the guest molecule to produce the molecularly imprinted polymer., 'a plurality of first structural units derived from monomers comprising (a) at least one functional moiety selected from an amino, —N(H)C(O)N(H), —N(H)—C(S)—N(H)—, pyridyl, imidazolyl, pyrimidinyl, pyrazinyl, or cyclenyl moiety, or any combination thereof, and (b) at least one polymerizable moiety, the molecularly imprinted polymer having a molecular imprint having a size and shape complementary to a lysophosphatidic acid, wherein the molecularly imprinted polymer is obtained by32. The molecularly imprinted polymer of claim 31 , wherein:(a) at least some of the monomers comprise a plurality of functional moieties capable of binding to a phosphate group;(b) the polymerizable moiety comprises a terminal ethenyl group; or(c) both (a) and (b).34. The molecularly imprinted polymer of claim 31 , further comprising a plurality of second structural units derived from monomers capable of binding to at least one of a phosphate acid group or a hydroxyl group claim 31 ...

Подробнее
Номер записи: 55
15-03-2018 дата публикации

Method for stabilizing glycerophospholipids and reagents using same

Номер: US20180074052A1
Автор: Takayuki Abe, Tetsuya Ota
Принадлежит: Sekisui Medical Co Ltd

Disclosed is an accurate and stable immunoassay reagent using a glycerophospholipid and a method for stabilizing the reagent. The reagent for assaying an analyte in blood by immune reaction with an antigen when the analyte is an antibody or with an antibody when the analyte is an antigen, wherein a glycerophospholipid and a polyvinylpyrrolidone are incorporated into the immune reaction system.

Подробнее
Номер записи: 56
19-03-2015 дата публикации

PC-O 44:6 - A BIOMARKER FOR VISCERAL ADIPOSITY

Номер: US20150080264A1
Автор: Guy Philippe Alexandre, Martin Francois-Pierre, Montoliu Roura Ivan, Rezzi Serge Andre Dominique
Принадлежит:

The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:6 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject. 1. A biomarker , wherein the biomarker is PC-O 44:6.2. (canceled)3. A method of diagnosing visceral adiposity in a subject , comprising:determining the level of PC-O 44:6 in a body fluid sample previously obtained from a subject to be tested, andcomparing the subject's PC-O 44:6 level to a predetermined reference value,wherein the predetermined reference value is based on an average PC-O 44:6 level in the same body fluid in a control population, andwherein a decreased PC-O 44:6 level in the sample compared to the predetermined reference value indicates an increased visceral adiposity.4. A method of diagnosing a change in visceral adiposity in a subject , comprising:determining the level of PC-O 44:6 in a body fluid sample previously obtained from a subject to be tested, andcomparing the subject's PC-O 44:6 level to a predetermined reference value,wherein the predetermined reference value is based on a PC-O 44:6 level in the same body fluid obtained from the same subject previously, andwherein a decreased PC-O 44:6 level in the sample compared to the predetermined reference value indicates increased visceral adiposity.5. A method of diagnosing the effect of a change in lifestyle on visceral adiposity in a subject , comprising:determining the level of PC-O 44:6 in a body fluid sample previously obtained from a subject to be tested, andcomparing the subject's PC-O 44:6 level to a predetermined reference value,wherein the predetermined reference value is based on a PC-O 44:6 level in the same body fluid obtained from the same subject previously, andwherein an increased PC-O 44:6 level in the ...

Подробнее
Номер записи: 57
05-03-2020 дата публикации

INLET INSTRUMENTATION FOR ION ANALYSER COUPLED TO RAPID EVAPORATIVE IONISATION MASS SPECTROMETRY ("REIMS") DEVICE

Номер: US20200075301A1
Автор: BALOG Julia, GODORHAZY Lajos, KARANCSI Tamás, Morris Michael Raymond, Pringle Steven Derek, Simon Daniel, SZALAY Daniel, Takáts Zoltán
Принадлежит:

An apparatus is disclosed comprising a first device for generating aerosol, smoke or vapour from one or more regions of a target, an inlet conduit to an ion analyser or mass spectrometer, the inlet conduit having an inlet through which the aerosol, smoke or vapour passes, and a Venturi pump arrangement arranged and adapted to direct the aerosol, smoke or vapour towards the inlet. 1. An apparatus comprising:a first device arranged and adapted to emit a stream of electrically charged droplets towards a target in use;a transfer capillary arranged and adapted to transfer ions generated from said target towards an ion analyser or mass spectrometer; anda heating device arranged and adapted to heat either: (i) a capillary of said first device; (ii) said stream of electrically charged droplets emitted from said first device; (iii) said target; and/or (iv) said transfer capillary.2. An apparatus as claimed in claim 1 , wherein said first device comprises a Desorption Electrospray Ionisation (“DESI”) device.3. An ion inlet device as claimed in claim 1 , wherein said heating device comprises a heater.4. An ion inlet device as claimed in claim 3 , wherein said heater comprises a wire heater.5. An ion inlet device as claimed in claim 1 , wherein said heating device is arranged and adapted to heat said capillary of said first device claim 1 , said stream of electrically charged droplets emitted from said first device claim 1 , said target or said transfer capillary to a temperature of above ambient temperature claim 1 , and/or to a temperature of at least 30° C. claim 1 , 50° C. claim 1 , 100° C. claim 1 , 200° C. claim 1 , 300° C. claim 1 , 400° C. claim 1 , 500° C. or greater than 500° C.6. An ion inlet device as claimed in claim 1 , wherein said heating device is located adjacent an inlet to said ion analyser or mass spectrometer.7. An ion inlet device as claimed in claim 6 , wherein said inlet forms the entrance to a first vacuum stage of said ion analyser or mass ...

Подробнее
Номер записи: 58
24-03-2016 дата публикации

Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses

Номер: US20160084855A1
Автор: Clark Robert B., Nichols Frank C.
Принадлежит: University of Connecticut

Methods for detecting inflammatory or autoimmune conditions, comprising analyzing bacterial L-serine containing lipids in a sample; and, comparing results of the analysis of the bacterial L-serine containing lipids in the sample with information on occurrence of the bacterial L-serine containing lipids in a control sample, wherein a decreased occurrence of the bacterial L-serine containing lipids in the test sample over the occurrence of bacterial L-serine containing lipids in the control sample indicates the presence of an inflammatory or an autoimmune condition, are described herein. An example of the autoimmune condition is multiple sclerosis (MS). The use of bacterial L-serine containing lipids as biomarkers for detection of MS is described. Antibodies specific to L-serine containing lipids and their uses are also provided. Also provided are compositions comprising bacterial L-serine containing lipids for modulating immune responses or TLR pathways in humans, animals, and human or animal cells or tissues. 176-. (canceled)77. A method for detecting an autoimmune condition in a test subject , comprising:extracting lipids from a test sample obtained from the test subject, thereby producing extracted lipids;analyzing the extracted lipids by mass spectrometry to quantify levels of one or more subclasses of bacterial L-serine containing lipids in the test sample; and,comparing the quantified levels of the one or more subclasses of bacterial L-serine containing lipids in the test sample to levels of the one or more subclasses of bacterial L-serine containing lipids in a control sample;wherein altered levels of the one or more subclasses of bacterial L-serine containing lipids in the test sample, in comparison to the levels in the control sample is indicative of a presence of the autoimmune condition in the test subject,wherein the test sample and the control samples are corresponding samples of human or animal bodily fluids or tissues,and wherein the control sample is ...

Подробнее
Номер записи: 59
24-03-2016 дата публикации

FATTY ACID PATTERN ANALYSIS FOR PREDICTING ACUTE CORONARY SYNDROME

Номер: US20160084857A1
Автор: Harris William S., Pottala James V., Shearer Gregory C.
Принадлежит:

The present invention provides blood based methods for predicting risk of acute coronary syndrome in a subject. 1. A method for predicting the risk of acute coronary syndrome (ACS) in a human subject , comprising:(a) measuring a combination of fatty acid markers in a fatty acid sample isolated from a blood component of a human subject, wherein the combination of the fatty acid markers, alone or together with the Framingham risk score (FRS) model, discriminates the ACS cases from controls better than the FRS model alone, the combination of the fatty acid markers comprising at least the following fatty acids: linoleic acid, gamma-linolenic acid, and docosahexaenoic acid (DHA);(b) comparing the amount of the fatty acid markers measured in the fatty acid sample to a control; and(c) predicting a risk of ACS based on the comparing in step (b), wherein the difference between the measured fatty acid markers and the control exceeding a statistical significance indicates a risk of ACS.2. The method of claim 1 , further comprising claim 1 , prior to the measuring step:identifying the combination of the fatty acid markers from a blood component of a human subject, wherein the combination of the fatty acid markers discriminates the ACS cases from controls better than the Framingham risk score (FRS) model.3. The method of claim 1 , wherein the combination of the fatty acid markers comprises linoleic acid claim 1 , gamma-linolenic acid claim 1 , DHA claim 1 , and eicosapentaenoic acid (EPA).4. The method of claim 1 , wherein the combination of the fatty acid markers further comprises one or more fatty acid selected from the group consisting of stearic acid claim 1 , alpha-linoleic acid claim 1 , palmitoleic acid claim 1 , arachidonic acid claim 1 , trans-palmitoleic acid claim 1 , eicosadienoic acid claim 1 , and trans-oleic acid.5. The method of claim 1 , wherein the combination of the fatty acid markers comprises linoleic acid claim 1 , gamma-linolenic acid claim 1 , DHA claim 1 ...

Подробнее
Номер записи: 60
23-03-2017 дата публикации

sPLA2 MONITORING STRIP

Номер: US20170081701A1
Автор: Cunningham Timothy J., Kollins Callaghan Katherine Marie, Yao Lihua
Принадлежит: DREXEL UNIVERSITY

A device and method for determining the presence or absence, or the level of, sPLA2 activity in a fluid sample. The device includes an absorbent matrix that defines a flow path for a fluid sample, a first region of the absorbent matrix for applying a fluid sample, where one of the components selected from a bioactive sPLA2 substrate and a label is dried onto or within the first region of the absorbent matrix, a second region of the absorbent matrix downstream of, and in fluid communication with, the first region for detecting an aggregated reaction product, where the other component not present in the first region is dried onto or within the second region of the absorbent matrix. 1. A device for detecting the presence or absence of sPLA2 in a fluid sample , comprising:an absorbent matrix that defines a flow path for a fluid sample; a first region of the absorbent matrix for applying a fluid sample, wherein one of the components selected from a bioactive sPLA2 substrate and a label is dried onto or within the first region of the absorbent matrix; anda second region of the absorbent matrix downstream of, and in fluid communication with, the first region for detecting an aggregated reaction product, wherein the other component not present in the first region is dried onto or within the second region of the absorbent matrix;wherein in the absence of sPLA2 in the fluid sample, applying the fluid sample does not result in a recognizable aggregated reaction product in the second region; andwherein in the presence of sPLA2 in the fluid sample, applying the fluid sample results in a detectable aggregated reaction product in the second region.2. The device of claim 1 , wherein the label comprises a gold sol.3. The device of claim 2 , wherein the gold sol comprises streptavidin coated gold particles.4. The device of claim 1 , wherein the bioactive sPLA2 substrate is Diheptanoyl Thio-PC.5. The device of claim 3 , further comprising a linker molecule dried onto or within the ...

Подробнее
Номер записи: 61
12-03-2020 дата публикации

Amyotrophic lateral sclerosis diagnostic composition using acid sphingomyelinase, and method for detecting diagnostic markers

Номер: US20200080129A1
Автор: Chang-Seok Ki, Hee Kyung Jin, Jae-Sung Bae, Ju Youn Lee, Seung Hyun Kim
Принадлежит: Industry Academic Cooperation Foundation of KNU, Industry University Cooperation Foundation IUCF HYU, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

The present invention relates to a amyotrophic lateral sclerosis (ALS) diagnostic composition using acid sphingomyelinase (ASM), and a method for detecting diagnostic markers and, more specifically, to a method and a composition for detecting markers for ALS, the method comprising the steps of: (a) providing a sample of a subject; (b) measuring the ASM expression level or the enzyme activation level in the sample; (c) determining that a subject, of which the ASM expression level or the enzyme activation level is increased compared to that of a normal person, has ALS. According to the investigation of the present inventors, the activity of ASM, among lipids and enzymes related to the sphingolipid metabolism, is specifically increased in a sample of an ALS patient compared to that of a normal person. ASM can be used as a marker for diagnosing ALS, thereby enabling the development of a novel and effective diagnostic reagent.

Подробнее
Номер записи: 62
31-03-2016 дата публикации

Use of MicroRNA or Inhibitors Thereof in Regulation of Lipid Metabolism

Номер: US20160089390A1
Автор: BIN Hong, FAN YANG, Huajun Jiang, LI Wang, Shuyi Si, Xiaojian Jia, Yu Du
Принадлежит: Institute of Medicinal Biotechnology of CAMS

The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.

Подробнее
Номер записи: 63
02-04-2015 дата публикации

COMPOSITIONS, METHODS AND USES FOR PEPTIDES IN DIAGNOSIS, PROGRESSION AND TREATMENT OF CANCERS

Номер: US20150093333A1
Автор: Morton Leslie, Saludes Jonel P., Yin Hang
Принадлежит:

Embodiments herein report compositions, systems, methods, and uses for diagnosing and/or treating a condition in a subject. In certain embodiments, one or more peptides can be used as biomarker detectors for predicting onset or progression of disease. Some embodiments of the present invention report peptides capable of associating with MVs for predicting onset or progression of cancer in a subject. Other embodiments include methods of generating and or modifying peptides of use herein. Yet other embodiments herein report biomarker detectors capable of detecting agents associated with cancer progression, for example, metastasis. 1. A composition comprising:a) a peptide derived from loop 3 of the C2B domain of Synaptotagmin I represented by GGDYDKIGKNDA (SEQ. ID NO:1) or GGXDYDKIGKNDANX (SEQ ID NO:13);b) a peptide derived a myristoylated alanine-rich C kinase substrate (MARCKS) effector domain;c) a trimeric peptide comprising peptides derived from Bradykinin; ord) a combination thereof; anda media.2. The composition of claim 1 , further comprising a side chain molecule or a tracking agent.3. The composition of claim 2 , wherein the side chain molecule or tracking agent comprises H claim 2 , acetyl group claim 2 , tryptophan claim 2 , 4-chloro-7-nitrobenzo-2-oxa-1 claim 2 ,3-diazole (NBD) claim 2 , sulfonated coumarin claim 2 , sulfonated rhodamine claim 2 , sulfonated xanthenes claim 2 , sulfonated cyanine or other fluorophor molecule.4. The composition of claim 1 , wherein the peptide comprises 5 or more consecutive amino acids of GGDYDKIGKNDA (SEQ. ID NO:1).5. The composition of claim 1 , wherein the peptide is a) and is a cyclic peptide.7. The composition of claim 1 , where the cyclic peptide comprises DYDKIGKNDAhaving a conservative amino acid substitution or deletion at any of amino acid D claim 1 , Y claim 1 , D claim 1 , K claim 1 , I claim 1 , G claim 1 , K claim 1 , N claim 1 , Dor A.8. The composition of claim 1 , comprising a) wherein X is selected from a ...

Подробнее
Номер записи: 64
30-03-2017 дата публикации

EXPRESSION OF VOLTAGE-GATED ION CHANNELS IN CILIATES

Номер: US20170089921A1
Автор: BEDNENKO Janna, BISHARYAN Yelena, CLARK Theodore G., COLUSSI Paul, PAPOYAN Ashot
Принадлежит:

Methods are disclosed for the production of mammalian voltage-gated ion channels in ciliates. In other aspects, compositions comprising lipid bilayers containing mammalian voltage-gated ion channels are disclosed. In other aspects, compositions comprising purified and reconstituted mammalian voltage-gated ion channels are disclosed. 1. A transgenic ciliate comprising:a transgene encoding a mammalian voltage-gated ion channel operably joined to regulatory sequences such that the ciliate expresses the voltage-gated ion channel protein.2. The transgenic ciliate of wherein the resting membrane potential of the ciliate differs from the resting membrane potential of a healthy native cell in which the voltage-gated ion channel protein is expressed by at least 10 mV3. The transgenic ciliate of wherein the resting membrane potential of the ciliate differs from the resting membrane potential of a healthy native cell in which the voltage-gated ion channel protein is expressed by at least 15 mV4. The transgenic ciliate of wherein the resting membrane potential of the ciliate differs from the resting membrane potential of a healthy native cell in which the voltage-gated ion channel protein is expressed by at least 20 mV.5. The transgenic ciliate of wherein the resting membrane potential of the ciliate is −15 mV to −40 mV.6. The transgenic ciliate of wherein the resting membrane potential of the ciliate is −25 mV to −35 mV.7. The transgenic ciliate of any one of - wherein the resting membrane potential of the ciliate is less polarized than the healthy native cell in which the voltage-gated ion channel protein is expressed.8. The transgenic ciliate of any one of - wherein the native cell is a mammalian cell selected from the group consisting of a skeletal muscle cell claim 1 , cardiac muscle cell claim 1 , smooth muscle cell claim 1 , astrocyte claim 1 , neuron claim 1 , lymphocyte claim 1 , kidney cell and ovarian cell.9. The transgenic ciliate of any one of - wherein the native ...

Подробнее
Номер записи: 65
05-05-2022 дата публикации

LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING

Номер: US20220137053A1
Автор: Chilton Floyd, Snider Ashley Jones, Snider Justin Michael
Принадлежит:

Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment.

Подробнее
Номер записи: 66
01-04-2021 дата публикации

DIGITALIZED HUMAN ORGANOIDS AND METHODS OF USING SAME

Номер: US20210096126A1
Автор: KIMURA Masaki, Takebe Takanori
Принадлежит:

Disclosed are digitized organoids comprising a detectable sensor, such as, for example, a Radio frequency identification (RFID) based sensor. Further disclosed are methods for making the digitized organoids. The disclosed methods allow for self-assembly mediated incorporation of ultracompact RFID sensors into organoids. Methods of using the digitized organoids are also disclosed. 1. A digitized organoid comprising a detectable sensor , preferably an RFID based sensor , wherein said digitized organoid comprises a lumen , and said detectable sensor is located within said lumen , preferably wherein said detectable sensor has a diameter of less than about 1 mm , more preferably wherein said digitized organoid is a liver organoid , more preferably wherein said liver organoid is capable of albumin secretion , bile transport , or a combination thereof.2. A pooled organoid composition comprising a plurality of digitized organoids comprising a detectable sensor according to claim 1 , wherein said digitized organoids comprise at least one organoid derived from a first donor and at least one organoid derived from a second donor claim 1 , more preferably wherein said plurality of organoids is derived from more than two donors claim 1 , more preferably wherein said plurality of organoids is derived from more than three donors claim 1 , more preferably wherein said plurality of organoids is derived from more than four donors claim 1 , more preferably wherein said plurality of organoids is derived from more than five donors claim 1 , more preferably wherein said plurality of organoids is derived from more than six donors claim 1 , more preferably wherein said plurality of organoids is derived from more than seven donors claim 1 , more preferably wherein said plurality of organoids is derived from more than eight donors claim 1 , more preferably wherein said plurality of organoids is derived from more than nine donors claim 1 , more preferably wherein said plurality of organoids is ...

Подробнее
Номер записи: 67
28-03-2019 дата публикации

Free Functional Annexin Levels in Plasma as a Biomarker of Cardiovascular Risk

Номер: US20190094244A1
Автор: Olivier P. BLANC-BRUDE
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes Paris 5

The present invention relates to a method for diagnosing the occurrence of a vascular dysfunction or a vascular injury in a subject, said method comprising a step consisting of determining in a plasma sample obtained from said subject the level of free annexin. The present invention further relates to a method for determining whether a subject is at risk for severe vasculopathy, cardiovascular complications and cardiovascular disease, said method comprising a step consisting of determining in a plasma sample obtained from said subject the level of free annexin. Preferably, the methods further comprise the steps consisting of determining the level of circulating phosphatidylserine positive (PS+) microparticles (MPs) in the plasma sample obtained from said subject and calculating the ratio free annexin/circulating PS+MPs. The invention also relates to a kit for use in a method according to the invention and to a phosphatidylserine antagonist, for use in a method of treatment of severe vasculopathy, cardiovascular complications and cardiovascular disease in a subject having a decreased level of free annexin as compared to a free annexin reference level, wherein the method comprises a determination of the free annexin level in a plasma sample of said subject. Preferably, a phosphatidylserine antagonist is for use in a method of treatment of severe vasculopathy, cardiovascular complications and cardiovascular disease in a subject having a decreased ratio of free annexin/circulating PS+MPs as compared to a free annexin/circulating PS−MPs reference ratio, wherein the method further comprises the steps consisting of determining the circulating PS+MPs level in said plasma sample and calculating the free annexin/circulating P8−MPs ratio.

Подробнее
Номер записи: 68
14-04-2016 дата публикации

COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS

Номер: US20160102151A1
Автор: HSU Tsui-Ling, Lin Chih-Wei, LOU Yi-Wei, Wong Chi-Huey, WU Chung-Yi, Wu Han-Chung, YEH Shih-Chi
Принадлежит:

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer. 1. An isolated humanized monoclonal glycoantibody that specifically binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1.2. The isolated humanized monoclonal glycoantibody of claim 1 , which further binds to Fucα1→2Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1 and Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1.3. The isolated glycoantibody of or claim 1 , wherein the antibody is an IgG or IgM.4. The isolated glycoantibody of claim 1 , which further binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1.5. The isolated glycoantibody of claim 4 , which further binds to Neu5Acα2-8→Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1.6. The isolated glycoantibody of or claim 4 , wherein the antibody is an IgG1.7. An isolated humanized monoclonal antibody that specifically binds to Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1 claim 4 , Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1 claim 4 , Fucα1→2Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1 claim 4 , Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1 claim 4 , GalNAcβ1→3Galα1→4Galβ1→4Glcβ1 and Neu5Acα2-8→Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1.8. The isolated antibody of claim 7 , wherein the antigen binding fragment is a Fab fragment claim 7 , a F(ab′)2 fragment claim 7 , or a single-chain Fv fragment.9. The isolated antibody of claim 7 , wherein the antibody comprised VH having SEQ ID NO: 147 or SEQ ID No:137 and VL having SEQ ID No: 148 or SEQ ID No:138.10. The isolated antibody claim 9 , or antigen-binding fragment ...

Подробнее
Номер записи: 69
16-04-2015 дата публикации

HYDROXY-SPHINGOMYELIN 22:1 AS A BIOMARKER FOR HEALTHY AGING

Номер: US20150105296A1
Автор: Collino Sebastiano, Guy Philippe Alexandre, Martin Francois-Pierre, Montoliu Roura Ivan, Rezzi Serge Andre Dominique
Принадлежит:

Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker. 1. A method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders , comprisingobtaining a serum sample from a subjectdetermining the level of SM-OH 22:1, in the sample, andcomparing the subject's SM-OH 22:1 level to a predetermined reference value,wherein the predetermined reference value is based on an average serum SM-OH 22:1 level in a control population, andwherein a lower serum SM-OH 22:1 level in the sample compared to the predetermined reference value indicates an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders.2. The method of claim 1 , further comprisingdetermining the level of at least one of LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, 9-oxo-HODE, PC-O 34:1, or LTE4 in the sample, andcomparing the subject's level of at least one of LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, 9-oxo-HODE, PC-O 34:1, or LTE4 to a predetermined reference value,wherein the predetermined reference value is based on average serum LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, 9-oxo-HODE, PC-O 34:1, or LTE4 level in a control population, andwherein a lower serum SM-OH 22:1 level in the sample and/or a lower serum LPC 18:0, SM 24:0, PC-O 40:1, 9-HODE, or 9-oxo-HODE level in the sample compared to the predetermined reference values indicate an increased likelihood to delay and/or avoid ageing related chronic inflammatory disorders, and/orwherein elevated serum PC-O 34:1 and/or LTE4 levels in the sample compared ...

Подробнее
Номер записи: 70
14-04-2016 дата публикации

BLOOD BASED METHODS OF ASSESSING ADOLESCENT DEPRESSION IN A SUBJECT

Номер: US20160103144A1
Автор: Christianson Andrew B., Harris William S., Pottala James V.
Принадлежит:

The present invention provides blood based methods for assessing adolescent depression in a subject. 1. A method for assessing adolescent depression in a subject , comprising(a) measuring an amount of one or more fatty acids in a tissue sample from a subject at risk of suffering from adolescent depression;(b) comparing the amount of the one or more fatty acids to a control; and(c) determining a probability that the adolescent subject has depression based on the comparison.2. The method of claim 1 , wherein the one or more fatty acids are selected from the group consisting of myristic acid claim 1 , palmitic acid claim 1 , palmitelaidic acid claim 1 , palmitoleic acid claim 1 , stearic acid claim 1 , elaidic acid claim 1 , oleic acid claim 1 , linolelaidic acid claim 1 , linoleic acid claim 1 , gamma linolenic acid claim 1 , cis-11-eicosenoic acid claim 1 , alpha-linolenic acid claim 1 , cis-11 claim 1 ,14-eicosadienoic acid claim 1 , cis-8-11-14-eicosatrienoic acid claim 1 , arachidonic acid claim 1 , lignoceric acid claim 1 , eicosapentaenoic acid (EPA) claim 1 , nervonic acid claim 1 , docosatetraenoic acid claim 1 , n-6 docosapentaenoic acid claim 1 , n-3 docosapentaenoic acid claim 1 , and docosahexaenoic acid (DHA).3. The method of claim 1 , wherein the one or more fatty acids are selected from the group consisting of linolelaidic acid claim 1 , palmitelaidic acid claim 1 , alpha-linolenic acid claim 1 , myristic acid claim 1 , gamma-linolenic acid claim 1 , docosatetraenoic acid claim 1 , palmitoleic acid claim 1 , linoleic acid claim 1 , arachidonic acid claim 1 , and cis-8-11-14-eicosatrienoic acid.4. The method of claim 3 , wherein the method comprises measuring the amount of two or more of the fatty acids.5. The method of claim 4 , wherein the method comprises measuring the amount of three or more fatty acids.6. The method of wherein the tissue sample comprises red blood cells claim 1 , whole blood claim 1 , serum claim 1 , platelets claim 1 , white blood ...

Подробнее
Номер записи: 71
26-03-2020 дата публикации

PLASMA AND LIVER LIPID SPECIES AS BIOMARKERS OF FATTY LIVER

Номер: US20200096524A1
Автор: Auwerx Johan, JHA Pooja
Принадлежит:

The invention relates to plasma or liver lipid species selected from the triacylglycerol (TAG) and cardiolipin (CL) lipid classes measured by LC-MS/MS and use thereof as diagnostic and prognostic biomarkers of fatty liver, as well as to monitor the efficacy of preventive and therapeutic measures to lower liver fat content. 1. A method for diagnosing a fatty liver disease or a predisposition therefor in a subject , said method comprisingproviding a sample derived from a subject suspected to suffer from a fatty liver disease,determining in the sample of a subject the amount of at least one plasma or liver triglyceride (TAG) biomarker selected from the group comprising TAG(52:2), TAG(54:3), TAG(56:3), TAG(50:2), TAG(52:5), TAG(52:4), TAG(54:6) or a combination thereof, and/or at least one liver cardiolipin (CL) biomarker and/or monolysocardiolipin (MLCL) biomarker selected from the group comprising CL(LLLL), MLCL(LLL), MLCL(LOO), MLCL(LLO), CL(LOOPo), CL(LLPoP), CL(LOOO), CL(OOOP) or a combination thereof,comparing the amount of the at least one plasma or liver triglyceride (TAG) biomarker, liver cardiolipin (CL) biomarker and/or monolysocardiolipin (MLCL) biomarker with a reference, wherein increase of TAG(52:2), TAG(54:3), TAG(56:3), TAG(50:2), MLCL(LOO), MLCL(LLO), CL(LOOPo), CL(LLPoP), CL(LOOO), CL(OOOP) or a combination thereof and/or decrease of TAG(52:5), TAG(52:4), TAG(54:6), CL(LLLL), MLCL(LLL) or a combination thereof is indicative for the fatty liver disease.2. A method for monitoring the progression of a fatty liver disease in a subject diagnosed to suffer from a fatty liver disease , said method comprisingproviding a sample derived from a subject diagnosed to suffer from a fatty liver disease,determining in the sample of a subject the amount of at least one plasma or liver triglyceride (TAG) biomarker selected from the group comprising TAG(52:2), TAG(54:3), TAG(56:3), TAG(50:2), TAG(52:5), TAG(52:4), TAG(54:6) or a combination thereof, and/or at least one ...

Подробнее
Номер записи: 72
04-04-2019 дата публикации

CERAMIDES FOR EVALUATING RISK OF CARDIOVASCULAR DISEASE

Номер: US20190101550A1
Автор: Ory Daniel S., PETERSON Linda, RAMACHANDRAN Vasan S., SCHAFFER Jean E., XANTHAKIS Venessa
Принадлежит:

The present disclosure provides the use of two very long chain ceramides for determining the risk of cardiovascular disease. 1. A method to determine if a subject is at risk of cardiovascular disease (CVD) , the method comprising:measuring an amount of ceramide 24:0, and optionally ceramide 22:0, in a biological sample obtained from the subject;comparing the amount of ceramide 24:0, and optionally ceramide 22:0, in the biological sample to a reference value; andclassifying the subject as at risk for CVD if the amount of ceramide 24:0, and optionally ceramide 22:0, is less than the reference value.2. The method of claim 1 , wherein the subject has no other risk factors for CVD.3. The method of claim 1 , wherein the subject has one or more risk factors for CVD.4. The method of claim 3 , wherein the one or more risk factors is selected from the group consisting of male gender claim 3 , body mass index (BMI) claim 3 , high blood pressure claim 3 , prior CVD claim 3 , high cholesterol claim 3 , and age.5. The method of claim 1 , wherein the CVD is coronary heart disease (CHD) or heart failure (HF).6. The method of claim 1 , wherein the CVD is selected from the group consisting of fatal and non-fatal CHD claim 1 , cerebrovascular disease (stroke or transient ischemic attach) claim 1 , peripheral arterial disease (intermittent claudication) claim 1 , and heart failure.7. The method of claim 5 , wherein the CHD is selected from the group consisting of myocardial infarction (MI) claim 5 , coronary insufficiency claim 5 , and angina pectoris.8. A method to prevent cardiovascular disease (CVD) in a subject claim 5 , the method comprising:measuring an amount of ceramide 24:0, and optionally ceramide 22:0, in a biological sample obtained from the subject;comparing the amount of ceramide 24:0, and optionally ceramide 22:0, in the biological sample to a reference value;classifying the subject as at risk for CVD if the amount of ceramide 24:0, and optionally ceramide 22:0, is less ...

Подробнее
Номер записи: 73
21-04-2016 дата публикации

METHOD OF MEASURING LIPOPROTEIN'S CAPACITY TO ACCEPT CHOLESTEROL

Номер: US20160109469A1
Автор: HARADA Amane, KIRIYAMA Maria, MIWA Keiko, MURAKAMI Katsuhiro, YOSHIKAWA Keiko
Принадлежит: SYSMEX CORPORATION

Provided is a method of measuring a lipoprotein's capacity to accept cholesterol including the steps of: 1. A method of measuring a lipoprotein's capacity to accept cholesterol comprising the steps of:bringing a lipoprotein in a sample into contact with labeled cholesterol to incorporate the labeled cholesterol into the lipoprotein;bringing the lipoprotein having the labeled cholesterol into contact with an antibody that binds to a lipoprotein to form a complex of the lipoprotein and the antibody; andmeasuring the label generated from the complex.2. The method according to claim 1 , wherein the lipoprotein is a high-density lipoprotein.3. The method according to claim 1 , wherein the labeled cholesterol is fluorescence-labeled cholesterol claim 1 , and the intensity of the fluorescence light from the complex is measured in the measurement step.4. The method according to claim 1 , wherein in the step of incorporating the labeled cholesterol into the lipoprotein claim 1 , the labeled cholesterol is esterified by the contact with the sample and the esterified labeled cholesterol is incorporated into the lipoprotein.5. The method according to claim 1 , wherein the step of incorporating the labeled cholesterol into the lipoprotein claim 1 , the step of forming the complex claim 1 , and the step of measuring the label are performed in a cell-free system.6. The method according to claim 1 , further comprising a step of removing labeled free cholesterol which is not incorporated into the lipoprotein after the incorporation of the labeled cholesterol into the lipoprotein.7. The method according to claim 1 , further comprising a step of separating labeled cholesterol from the complex by removing the labeled free cholesterol which is not incorporated into the lipoprotein after the step of forming a complex.8. The method according to claim 1 , wherein the antibody that binds to a lipoprotein is an anti-ApoAI antibody.9. The method according to claim 8 , wherein the anti-ApoAI ...

Подробнее
Номер записи: 74
21-04-2016 дата публикации

METHOD FOR THE DIAGNOSIS OF NIEMANN-PICK DISEASE

Номер: US20160109470A1
Автор: Mascher Hermann, Rolfs Arndt
Принадлежит:

The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject, wherein the biomarker is compound 509. 1. A method for diagnosing Niemann-Pick disease in a subject , wherein the method comprises detecting a biomarker in a sample from the subject , wherein the biomarker is compound 509.2. The method according to claim 1 , wherein the method further comprises determining a level of the biomarker present in the sample.3. The method according to claim 1 , wherein the level of the biomarker is indicative whether or not the subject is suffering from Niemann-Pick disease or whether or not the subject is at risk of suffering from Niemann-Pick disease.45-. (canceled)6. The method according to claim 1 , wherein the method further comprises applying claim 1 , maintaining claim 1 , reducing claim 1 , elevating or not applying a therapy based on whether the subject is suffering from Niemann-Pick disease or is at risk of suffering from Niemann-Pick disease.710-. (canceled)11. The method according to claim 1 , wherein the empirical formula of compound 509 is CHONP as quasimolecular M+H ion and compound 509 has a quasimolecular M+H ion molecular weight of 509.3 and claim 1 , respectively claim 1 , a [M+H] of 509.265 (m/z) (as a monoisotopic quasimolecular M+H ion) claim 1 , determined by MALDI-RTOF-KS and/or Orbitrap LTQ-XL.13. The method according to claim 1 , wherein the method comprises detecting at least one additional biomarker in a or in the sample from the subject.14. The method according to claim 13 , wherein the method comprises determining the level of the at least one additional biomarker in a or in the sample from the subject.15. The method according to claim 13 , wherein the at least one additional biomarker is selected from the group consisting of free lyso-sphingomyelin claim 13 , and wherein the at least one additional biomarker is ...

Подробнее
Номер записи: 75
19-04-2018 дата публикации

Lipid Markers for Early Diagnosis of Breast Cancer

Номер: US20180106808A1
Автор: Youping Deng
Принадлежит: RUSH UNIVERSITY MEDICAL CENTER

Methods for measuring a panel of biomarkers in a subject suspected of having breast cancer are provided. The methods include obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample, the panel comprising at least 5 biomarkers selected from the group comprising LPC(18:3), LPC(20:2), LPC(20:1), LPC(20:0), PC(32:1), PC(34:4), PC(38:3), PC(40:5), PC(40:3), PC(44:11), ePC(32:2), ePC(38:3), C19:1 CE, C19:0 CE, and C20:0 CE, wherein the measurement comprises measuring a level of each of the at least 5 biomarkers.

Подробнее
Номер записи: 76
20-04-2017 дата публикации

HOPANOIDS PRODUCING BACTERIA AND RELATED BIOFERTILIZERS, COMPOSITIONS, METHODS AND SYSTEMS

Номер: US20170107160A1
Автор: BELIN Brittany Jo, Kulkarni Gargi, NEWMAN Dianne K.
Принадлежит:

Hopanoids, hopanoids-producing nitrogen-fixing bacteria, and related formulations, systems and methods are described herein. In particular, hopanoids alone or in combination with hopanoid-producing nitrogen-fixing bacteria can be used as biofertilizer to stimulate plant growth and yield with enhanced tolerance to diverse stresses found in plant-microbe symbiotic microenvironments. 1. A biofertilizer for a leguminous plant essentially consisting of one or more nitrogen-fixing rhizobia capable of producing Chopanoids , in a form suitable for administration to one or more leguminous plant or seed , and/or for administration to a soil surrounding the one or more leguminous plant or seed.2. The biofertilizer of claim 1 , the biofertilizer in combination with carrier allows increased stability claim 1 , viability and/or effectiveness of the nitrogen-fixing bacteria gas exchange of the one or more nitrogen-fixing rhizobia.3. The biofertilizer of claim 1 , wherein the one or more nitrogen-fixing rhizobia are nitrogen-fixing rhizobia naturally capable of producing Chopanoids.4Bradyrhizobium.. The biofertilizer of claim 3 , wherein the one or more nitrogen-fixing rhizobia comprise at least one5BradyrhizobiumBradyrhizobium japonicum, Bradyrhizobium diazoefficiens, BradyrhizobiumMethylobacterium nodulans.. The biofertilizer of claim 3 , wherein the one or more nitrogen-fixing rhizobia comprise BTAi1 claim 3 , ORS278 claim 3 , and6. The biofertilizer of claim 1 , wherein the one or more nitrogen-fixing rhizobia are nitrogen-fixing rhizobia naturally incapable of producing Chopanoids and genetically engineered to include a set of genes enabling production of Chopanoids by the one or more nitrogen-fixing rhizobia.7Rhizobium etli, Rhizobium leguminosarum, Mesorhizobium loti, Sinorhizobium meliloti, Azorhizobium caulinodansOchrobactrum anthropi.. The biofertilizer of claim 5 , wherein the one or more nitrogen-fixing rhizobia comprise claim 5 , and8. A method to provide the ...

Подробнее
Номер записи: 77
02-04-2020 дата публикации

DIRECTED EVOLUTION OF MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO TARGET PROTEINS

Номер: US20200102555A1
Автор: Guillen Schlippe Yollete V., Horiya Satoru, KRAUSS Isaac J.
Принадлежит:

The invention relates to a method for selecting a glycopolypeptide that binds to a target protein, the method including the steps of providing a pool of glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex; combining the pool with a target protein to form a mixture; incubating the mixture for a period of time sufficient to allow any target protein to bind to one or more of the glycopolypeptides, thereby forming glycopolypeptide-target protein complexes; and isolating from the mixture the glycopolypeptide-target protein complexes, thereby identifying a plurality of selected glycopolypeptides. 1. A method for selecting a glycopolypeptide that binds to a target protein comprising:{'sup': '11', 'providing a pool of glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex, wherein the provided pool comprises greater than 10glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex;'}combining the pool with a target protein to form a mixture;incubating the mixture for a period of time sufficient to allow any target protein to bind to one or more of the glycopolypeptides, thereby forming glycopolypeptide-target protein complexes; andisolating from the mixture the glycopolypeptide-target protein complexes, thereby identifying a plurality of selected glycopolypeptides.23-. (canceled)4. The method according to claim 1 , wherein the provided pool comprises greater than 10glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex.5. The method according to claim 1 , wherein the provided pool comprises about 10glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex.67-. (canceled)8. The method according to claim 1 , wherein said incubating is carried out at a temperature from about 32° C. to about 42° C.9. The method according to claim 1 , wherein said isolating comprises:exposing the mixture to magnetic beads labeled with an affinity reagent that binds to a portion of the target ...

Подробнее
Номер записи: 78
02-04-2020 дата публикации

REAGENT FOR DETERMINATION OF COAGULATION TIME, PRODUCTION METHOD THEREFOR, REAGENT KIT, AND METHOD FOR DETERMINATION OF COAGULATION TIME

Номер: US20200103421A1
Автор: AKATSUCHI Kohei, AKI Masako, BANDOU Takahiko, Yamamoto Naoki
Принадлежит: SYSMEX CORPORATION

Disclosed is a reagent for determination of activated partial thromboplastin time, comprising: a phosphatidylcholine (PC); a phosphatidylserine (PS); and a phosphatidylethanolamine (PE), wherein a concentration ratio of the PS relative to the PC is not less than 0.16 and not more than 0.25, and a concentration of the PS is not less than 7 μg/mL and not more than 13 μg/mL. 1. A reagent for determination of activated partial thromboplastin time , comprising:a phosphatidylcholine (PC);a phosphatidylserine (PS); anda phosphatidylethanolamine (PE), whereina concentration ratio of the PS relative to the PC is not less than 0.16 and not more than 0.25, anda concentration of the PS is not less than 7 μg/mL and not more than 13 μg/mL.2. The reagent according to claim 1 , wherein a concentration of the PC in the reagent is not less than 28 μg/mL and less than 50 μg/mL.3. The reagent according to claim 1 , wherein a concentration of the PC in the reagent is more than 50 μg/mL and not more than 60 μg/mL.4. The reagent according to claim 1 , wherein a concentration of the PE in the reagent is more than 9 μg/mL and less than 25 μg/mL.5. The reagent according to claim 1 , comprising an activator.6. The reagent according to claim 5 , wherein the activator is at least one selected from the group consisting of an ellagic acid compound claim 5 , silica claim 5 , kaolin claim 5 , and celite.7. The reagent according to claim 6 , whereinthe activator is the ellagic acid compound, anda concentration of the ellagic acid compound in the reagent is not less than 10 μM and not more than 400 μM.8. The reagent according to claim 1 , comprising a metal ion-forming compound.9. The reagent according to claim 8 , wherein the metal ion-forming compound is a salt of at least one metal selected from zinc claim 8 , manganese claim 8 , aluminum claim 8 , and nickel.10. The reagent according to claim 1 , wherein phospholipids are in a form of liposomes.11. The reagent according to claim 10 , wherein the ...

Подробнее
Номер записи: 79
02-04-2020 дата публикации

DETERMINATION OF CHOLESTEROL ESTERASE

Номер: US20200103424A1
Автор: BROCIA Robert W.
Принадлежит: Roar Holding LLC

Advantage is taken of macrolide antibiotics' complexation with free cholesterol to yield fluorescent complexes to determine the levels of free cholesterol, total cholesterol, or lecithin: cholesterol acyl transferase (LCAT) in serum or plasma or fractions thereof or to determine the level of cholesterol esterase in a sample. 1. A method to detect and quantitate total cholesterol (TC) in a sample which method comprises:adding to the sample an amount of cholesteryl esterase effective to hydrolyze any cholesteryl ester (CE) in said sample; andcontacting said sample with a macrolide antibiotic that forms a complex with free cholesterol (FC) which complex is fluorescent upon excitation; andquantitating the level of fluorescence as a measure of the concentration of FC in said sample whereby the total cholesterol (TC) in said sample is thereby determined.2. The method of wherein the sample comprises serum claim 1 , plasma or fraction thereof3. The method of wherein the sample consists essentially of high-density lipoprotein particles (HDL) from said serum or plasma.4. The method of wherein the macrolide antibiotic is pimaricin claim 1 , amphotericin B claim 1 , nystatin claim 1 , lucensomycin claim 1 , fungichromin (lagosin) or filipin.5. The method of wherein said sample is maintained at a temperature below room temperature or wherein an inhibitor of lecithin: cholesterol acyl transferase (LCAT) is added to the sample.6. The method of wherein the inhibitor is iodoacetate claim 5 , an anti-LCAT antibody or an aptamer specific for LCAT.7. A method to measure the activity of cholesterol esterase (CE) in a sample which method comprises:a) incubating said sample for a period of time with a macrolide antibiotic that forms a complex with FC which complex exhibits fluorescence upon excitation; andb) quantitating the fluorescence at a plurality of times within said period so as to measure the concentration of FC as a function of time over said period; orc) incubating said sample ...

Подробнее
Номер записи: 80
26-04-2018 дата публикации

METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS AND PREDICTION OF CLINICAL SENSITIVITY TO TREATMENT OF BILE ACID-RELATED DISORDERS

Номер: US20180110834A1
Автор: DEPAOLI Alexander Mark, LUO Jian, Tian Hui
Принадлежит:

Provided herein are methods of using 7a-hydroxy-4-cholsten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). 178.-. (canceled)79. A method of [ (a) administering the treatment peptide to a subject having a bile acid-related or associated disorder;', '(b) obtaining a test sample from the subject;', '(c) determining the level of 7a-hydroxy-4-cholsten-3-one (C4) in the test sample; and', '(d) identifying the subject as being likely to be responsive to the treatment peptide if the level of C4 in the test sample of the subject decreases as compared to a reference level of C4;, '(ii) predicting the responsiveness of a subject having or suspected of having a bile acid-related or associated disorder to a treatment peptide; comprising, 'wherein the method further comprises administering the treatment peptide to the subject identified as being likely to be responsive to a treatment of the bile acid-related or associated disorder with the treatment peptide; or, '(A) (i) identifying a subject having or suspected of having a bile acid-related or associated disorder who is likely to be responsive to a treatment peptide; or'} (a) administering the treatment peptide to a subject having a bile acid-related or associated disorder;', '(b) obtaining a test sample from the subject;', '(c) determining the level of C4 in the test sample; and', '(d) comparing the level of C4 in the test sample with a reference level of C4, wherein a decrease in the level in the test sample as compared to the reference level is indicative of the efficacy of the treatment peptide in treating the bile acid ...

Подробнее
Номер записи: 81
26-04-2018 дата публикации

SCREENING ASSAYS BASED ON MAG AND/OR ABHD6 FOR SELECTING INSULIN SECRETION PROMOTING AGENT

Номер: US20180113115A1
Автор: Joly Erik, Madiraju Murthy, Prentki Marc
Принадлежит:

The present application relates to a method of characterizing an agent's ability to increase insulin secretion in a subject. The method comprises determining whether the agent is able to modulate MAG level at the inner surface of the cytoplasmic membrane of a cell and/or ABHD6 activity. The agent is characterized as having the ability to increase insulin secretion in the subject when it is capable of upregulating MAG level at the inner surface of the cytoplasmic membrane and/or downregulating ABHD6 activity. 1. A method of characterizing an agent's ability to increase glucose-stimulated insulin secretion in a subject , said method comprising:(a) combining the agent with a pancreatic β cell expressing a ABHD6 polypeptide, in the presence of at least 10 mM of glucose;(b) determining a test value of the lipase activity specific for the ABHD6 polypeptide of the pancreatic β cell in the presence of the agent and of glucose, wherein the test value is obtained by measuring, in the pancreatic β cell, a test level of intracellular monoacyl glycerol (MAG), a test level of extracellular glycerol and a test level of extracellular free fatty acid;(c) providing a control value of the lipase activity of the ABHD6 polypeptide, wherein the control value is associated with a lack of ability to increase insulin secretion in the subject and wherein the control value comprises a control level of intracellular MAG, a control level of extracellular glycerol and a control level of extracellular free fatty acid;(d) comparing the test value of step (b) to the control value of step (c); and i. having the ability to increase glucose-stimulated insulin secretion in the subject when the test level of intracellular MAG is increased with respect to the control level of intracellular MAG, the test level of extracellular glycerol is decreased with respect to the control level of extracellular glycerol and the test level of extracellular free fatty acid is decreased with respect to the control level ...

Подробнее
Номер записи: 82
26-04-2018 дата публикации

Serum Biomarker For Hepatocellular Carcinoma (HCC)

Номер: US20180113135A1
Автор: Ferreirós Nerea, Grammatikos Georgios, Pfeilschifter Josef, Zeuzem Stefan
Принадлежит:

The present invention pertains to novel diagnostic procedures for the prognosis, diagnosis and monitoring of liver diseases such as hepatocellular carcinoma (HCC). The present invention provides sphingolipids and especially long chain ceramides as significant and highly prognostic serum biomarkers in HCC compared to liver cirrhosis. Therefore the invention in particular provides a method for detecting the presence or absence of a HCC in a liver cirrhosis patient using the disclosed biomarkers. Also provided is a method for monitoring the treatment success of a HCC treatment by monitoring the disclosed serum biomarkers. Finally the invention pertains to diagnostic kits for performing the disclosed methods of the invention. 1. A non-invasive method of predicting , monitoring and/or diagnosing hepatocellular carcinoma (HCC) in a subject , comprising determining the level of one or more biomarkers selected from the group of sphingolipids in a biological sample from the subject.2. The method according to claim 1 , further comprising the steps of:a) Providing the biological sample from the subject;b) Determining the level of one or more biomarkers selected from the group of sphingolipids in the biological sample;c) Comparing the level of the one or more biomarkers in the biological sample to a control level of the one or more biomarkers, andWherein a different level of the one or more biomarkers in the biological sample compared to the control level is indicative for the presence or absence of HCC in the subject.3. The method according to claim 1 , wherein the one or more biomarkers is selected from a long chain ceramide claim 1 , or a long chain dihydroceramide.4. The method according to any of claim 1 , wherein the one or more biomarkers is selected from a C16 to C24 Ceramide or a C16 to C24 dihydroceramide.5. The method according to claim 1 , wherein the one or more biomarkers is selected from the group C16DHC claim 1 , C18DHC claim 1 , C16Cer claim 1 , and S1P claim 1 ...

Подробнее
Номер записи: 83
27-04-2017 дата публикации

METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID

Номер: US20170114125A1
Автор: GARLAND William Arthur, HANSEN Genevieve, MATTEO Rosalia, Sabbadini Roger A., Swaney James Stephen
Принадлежит:

Methods for preventing or treating pain are provided, comprising administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA. 1. A method of treating or preventing a disease or disorder associated with aberrant levels of lysophosphatidic acid (LPA) , comprising administering to a subject , optionally a human subject , in need of such treatment an antibody or fragment thereof that binds LPA under physiological conditions in an amount effective to reduce in vivo the effective concentration of LPA , thereby effecting treatment or prevention of the disease or disorder , wherein the antibody or fragment thereof that binds lysophosphatidic acid (LPA) under physiological conditions comprises at least one heavy chain variable domain and at least one light chain variable domain , wherein(i) each heavy chain variable domain comprises first, second, and third heavy chain complementarity determining regions (CDRs), wherein the first heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 7, 8, 17 and 23, the second heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 9, 13 and 18, and the third heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 10, 14, 16 and 19; and 'wherein the disease or disorder is selected from the group consisting of a hyperproliferative disease, including cancer; an immune-related disease, including an autoimmune disease, allograft rejection and graft-vs-host disease; obesity; type 2 diabetes; an ocular disease, including macular degeneration; pain; a disease associated with aberrant angiogenesis or neovascularization; apoptosis; fibrogenesis or fibrosis, including scleroderma, pulmonary fibrosis, renal fibrosis, skin fibrosis, cardiac fibrosis, and hepatic fibrosis; wound repair and healing; and spider bite.', '(ii) each light chain variable domain comprises first, ...

Подробнее
Номер записи: 84
27-04-2017 дата публикации

METHOD AND KIT FOR QUANTIFYING CARDIOLIPIN

Номер: US20170114387A1
Автор: MORITA Shin-ya
Принадлежит:

The inventions disclosed herein are a method for quantifying cardiolipin in a sample, comprising the steps of: (1) treating the sample with phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase and (2) measuring the fluorescence intensity, absorbance, or luminescence intensity of a compound generated in step (1) to quantify cardiolipin using a calibration curve obtained beforehand; and a kit for quantifying cardiolipin comprising phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase. 1. A method for quantifying cardiolipin in a sample , comprising the steps of:(1) treating the sample with phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase and(2) measuring the fluorescence intensity, absorbance, or luminescence intensity of a compound generated in step (1) to quantify cardiolipin using a calibration curve obtained beforehand.2. The method according to claim 1 , wherein in step (1) claim 1 , the sample is treated with enzymes in two steps:(a) a step of treating with phospholipase D and(b) a step of treating with glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase.3Streptomyces.. The method according to claim 1 , wherein the phospholipase D is derived from a microorganism belonging to the genus4Streptomyces chromofuscus.. The method according to claim 1 , wherein the phospholipase D is derived from a microorganism belonging to5. A kit for quantifying cardiolipin comprising phospholipase D claim 1 , glycerol kinase claim 1 , glycerol-3-phosphate oxidase claim 1 , and peroxidase.6Streptomyces.. The kit according to claim 5 , wherein the phospholipase D is derived from a microorganism belonging to the genus7Streptomyces chromofuscus.. The kit according to claim 5 , wherein the phospholipase D is derived from a microorganism belonging to The present invention relates to a method for quantifying cardiolipin and a kit for quantifying cardiolipin.Cardiolipin (hereinafter sometimes referred ...

Подробнее
Номер записи: 85
09-06-2022 дата публикации

QUANTITATIVE DETERMINATION METHOD FOR Hex4, LYSO-GM1, Fuc-GlcNAc-Asn, AND LYSO-SULFATIDE INCLUDED IN CEREBROSPINAL FLUID

Номер: US20220178937A1
Автор: FUKATSU Tomoki, HASHIMOTO Hidehiko, Tanaka Noboru, TANAKA Satowa
Принадлежит: JCR PHARMACEUTICALS CO., LTD.

A method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfatide included in cerebrospinal fluid, the method including adding an internal standard substance to a solution including the cerebrospinal fluid, submitting the solution including the cerebrospinal fluid, to which the internal standard substance has been added, to liquid chromatography to obtain an eluate, and subjecting the eluate to mass analysis. 1. A method for quantifying a substance in cerebrospinal fluid , comprising:adding an internal standard substance to a solution including the cerebrospinal fluid;applying the solution containing the cerebrospinal fluid, to which the internal standard substance has been added, to liquid chromatography to obtain an eluate; andsubjecting the eluate to mass analysis to quantify the substance.2. The method according to claim 1 , wherein the substance contained in the cerebrospinal fluid is Hex4.3. The method according to claim 2 , wherein the liquid chromatography is hydrophilic interaction liquid chromatography.4. The method according to claim 2 , wherein the Hex4 is measured in comparison with the internal standard substance.6. The method according to claim 2 , wherein the cerebrospinal fluid is from a patient with a disease in which Hex4 and/or glycogen accumulates in a body.7. The method according to claim 6 , wherein the disease is Pompe disease.8. The method according to claim 6 , wherein the patient has received treatment to reduce Hex4 and/or glycogen present in the body.9. The method according to claim 1 , wherein the substance in the cerebrospinal fluid is lyso-monosialoganglioside GM1.10. The method according to claim 9 , wherein the liquid chromatography is reverse phase chromatography.11. The method according to claim 9 , wherein the lyso-monosialoganglioside GM1 is measured in comparison with the internal standard substance.13. The method according to claim 9 , wherein the cerebrospinal fluid is from a patient with a disease in which lyso- ...

Подробнее
Номер записи: 86
09-06-2022 дата публикации

STRATIFICATION BY SEX AND APOE GENOTYPE IDENTIFIES METABOLIC HETEROGENEITY IN ALZHEIMER'S DISEASE

Номер: US20220178954A1
Автор: Arnold Matthias, Kaddurah-Daouk Rima F., Kastenmüller Gabi
Принадлежит:

Described herein are methods for stratifying Alzheimer's disease among male and female subjects by analyzing biomarker metabolites. In one aspect, the biomarker metabolite comprises one or more of PC ae C44:4, PC ac C44:5, or PA ae C44:6; or PC ac C44:4, PC ac C44:5, PC aa C32:1, PC aa C32:0, or PC ae C42:4. 1. A method for stratifying Alzheimer's disease among male and female subjects , the method comprising:determining in a sample from the subject the level of at least one biomarker metabolite selected from the group consisting of PC ae C44:4, PC ae C44:5, PA ae C44:6, PC aa C32:1, PC aa C32:0, and PC ae C42:4; anddiagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.2. The method of claim 2 , wherein the biomarker metabolites are selected from PC ae C44:4 claim 2 , PC ae C44:5 claim 2 , and PA ae C44:6.3. The method of claim 2 , wherein the biomarker metabolites are selected from PC ae C44:4 claim 2 , PC ae C44:5 claim 2 , PC aa C32:1 claim 2 , PC aa C32:0 claim 2 , and PC ae C42:4.4. A method of diagnosing or detecting Alzheimer's disease in a male subject claim 2 , the method comprising:determining in a sample from the subject the level of at least one biomarker metabolite selected from the group consisting of PC ae C32:1, threonine, PC ae C36:1, PC ae C36:2, asparagine, glycine, one hydroxy-SM (SM (OH) C16:1), PC ae C40:2, and C16:1; anddiagnosing the subject as having Alzheimer's disease or an increased risk of Alzheimer's disease when the level of the at least one biomarker metabolite in the sample from the subject is different from or greater than the level in a control.5. The method of claim 4 , wherein the biomarker metabolites comprise PC ae C32:1.6. The method of claim 4 , wherein the biomarker metabolites comprise threonine.7. The method of claim 4 , wherein the ...

Подробнее
Номер записи: 87
18-04-2019 дата публикации

BIOMARKER FOR THE DIAGNOSIS OF PULMONARY HYPERTENSION (PH)

Номер: US20190113530A1
Автор: Bordag Natalie, GANDER Edgar, MAGNES Christoph, NAGY Bence M., NARATH Sophie, Olschewski Andrea, OLSCHEWSKI Horst
Принадлежит:

The present invention relates to a method of diagnosing pulmonary hypertension (PH) in a patient, a method of monitoring the course of pulmonary hypertension in a patient, a method of determining the severity of pulmonary hypertension in a patient, and a method of differentiating between pulmonary hypertension and at least one condition selected from a group consisting of a disease associated with a risk of developing pulmonary hypertension and metabolic syndrome. In addition, the present invention relates to a kit comprising means for carrying out the above methods. 1. A method of diagnosing pulmonary hypertension (PH) in a patient comprising the step of:determining the level of one or more free fatty acids (FFA) in a biological sample from a patient.3. The method of claim 1 , wherein the step of determining the level of one or more free fatty acids in a biological sample from a patient comprisesdetermining the level of one or more first free fatty acids and the level of one or more second free fatty acids, and wherein preferably the method further comprises the step of:determining the ratio of the level of one or more first free fatty acids and the level of one or more second free fatty acids.4. A method of monitoring the course of pulmonary hypertension in a patient comprising the step of:determining the level of one or more free fatty acids in a biological sample from a patient.5. The method of claim 4 , wherein the method further comprises the step of:determining the level of one or more compounds selected from the group consisting of triacylglyceroles (TAGs), diacylglyceroles (DAGs), membrane lipids, and lysolipids, and wherein preferably the method further comprises the step of:determining the ratio of the level of one or more free fatty acids and the level of one or more compounds selected from the group consisting of triacylglyceroles (TAGs), diacylglyceroles (DAGs), membrane lipids, and lysolipids.7. A method of determining the severity of pulmonary ...

Подробнее
Номер записи: 88
18-04-2019 дата публикации

CERAMIDES AND THEIR USE IN DIAGNOSING CVD

Номер: US20190113531A1
Автор: Laaksonen Reijo
Принадлежит:

The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications. 12-. (canceled)4. (canceled)69.-. (canceled)10. The method of claim 3 , wherein the concentrations of the at least one ceramide of Formula (I) and the at least one ceramide of Formula (II) are determined using a mass spectrometry instrument claim 3 , and optionally wherein the mass spectrometry instrument coupled to a direct sample infusion method or to a high performance separation method.11. (canceled)12. The method of claim 3 , wherein concentrations of at least at least 3 claim 3 , at least 4 claim 3 , at least 5 or at least 6 ceramides of Formula (I) and/or at least 2 claim 3 , at least 3 claim 3 , at least 4 claim 3 , at least 5 or at least 6 ceramides of Formula (II) are determined.1314-. (canceled)15. The method of claim 3 , wherein the concentrations of the following ceramides of Formula (II) are determined: Cer(d18:1/16:0) claim 3 , Cer(d18:1/18:0) and/or Cer(d18:1/24:1) and/or wherein the concentration of the following ceramide of Formula (I) is determined: Cer(d18:1/24:0).16. (canceled)17. The method of claim 3 , wherein the one or more CV complications are one or more of AMI (acute myocardial infarction) claim 3 , ACS (acute coronary syndrome) claim 3 , stroke claim 3 , or CV death.18. The method of claim 3 , further comprising ...

Подробнее
Номер записи: 89
09-04-2020 дата публикации

METHOD FOR EVALUATION OF DRUG EFFICACY OF A MEDICINE HAVING A THERAPEUTIC OR PREVENTIVE EFFECT AGAINST A DISEASE RELATED TO EL ACTIVITY AND A METHOD FOR SCREENING AN INHIBITOR OF EL ACTIVITY

Номер: US20200109433A1
Автор: Ono Takashi, SHIGAKI Shuhei, YAMAMOTO Atsuko
Принадлежит: Shionogi & Co., Ltd.

The present invention is related to a method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity wherein phosphatidylinositol or lysophosphatidylinositol is used as an indicator. The present invention is also related to a method for screening an inhibitor of EL activity using phosphatidylinositol and a kit for use in the method. 1. A method for measurement of EL activity , wherein phosphatidylinositol or lysophosphatidylinositol is used as an indicator.2. A method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity , comprising(1) a step for comparing a concentration of phosphatidylinositol or lysophosphatidylinositol in a sample obtained from a mammal after the administration of a test substance with a concentration of phosphatidylinositol or lysophosphatidylinositol in a sample obtained from the mammal before the administration of the test substance, and(2) a step for evaluating the test substance as a medicine having a therapeutic or preventive effect against a disease related to EL activity when the concentration of phosphatidylinositol or lysophosphatidylinositol in the sample obtained from the mammal after the administration of the test substance is altered relative to the concentration of phosphatidylinositol or lysophosphatidylinositol in the sample obtained from the mammal before the administration of the test substance.3. The method described in claim 2 , wherein the sample is blood claim 2 , serum or plasma. This application is a 37 C.F.R. § 1.53(b) divisional of U.S. application Ser. No. 15/611,316 filed on Jun. 1, 2017, which is a 37 C.F.R. § 1.53(b) divisional of U.S. application Ser. No. 14/437,941 filed on Apr. 23, 2015 (now U.S. Pat. No. 9,695,462 B2 issued Jul. 4, 2017), which is the National Phase of PCT International Application No. PCT/JP2013/079814, filed on Nov. 5, 2013, which claims priority ...

Подробнее
Номер записи: 90
05-05-2016 дата публикации

MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF

Номер: US20160120958A1
Автор: Chuang Wei-Lien, Cox Gerald F., ZHANG Kate X.
Принадлежит: Genzyme Corporation

The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy. 1. A method of treating a human subject having an acid sphingomyelinase (ASM) disorder , comprising:(a) administering to the subject a first dose of a therapeutic agent for treating an ASM disorder having a first concentration; and(b) administering to the subject a second dose of therapeutic agent having a second concentration equal to or greater than the first concentration if the subject has been determined to have a level of lyso-sphingomyelin (lyso-SPM) that is less than or equal to a reference level after administration of the first dose.2. The method of claim 1 , further comprising repeating the process of steps (a)-(b) at increasing dose concentrations until the subject is determined to have a level of lyso-SPM that is greater than the reference level.3. The method of or claim 1 , wherein determining the level of lyso-SPM in the subject comprises(a) collecting a biological sample from the subject;(b) measuring the level of lyso-SPM in the biological sample; and(c) comparing the level of lyso-SPM in the sample to a reference level.4. The method of any one of - claim 1 , further comprising maintaining the dose claim 1 , decreasing the dose claim 1 , or discontinuing administration of the therapeutic agent if the level of lyso-SPM in the subject is determined to be greater than the reference level.5. The method of any one of - claim 1 , wherein each successively higher concentration dose of therapeutic agent is administered one claim 1 , two claim 1 , three claim 1 , four claim 1 , five claim 1 , six claim 1 , or seven days claim 1 , or one claim 1 , two claim 1 , three or four weeks after the previous dose.6. The method of any one of - claim 1 , ...

Подробнее
Номер записи: 91
05-05-2016 дата публикации

G-PROTEIN COUPLED RECEPTOR (GPCR)-BASED BIOSENSORS AND USES THEREOF

Номер: US20160122832A1
Автор: Bhattacharyya Souryadeep, Mukherjee Kuntal, Peralta-Yahya Pamela, SARRIA STEPHEN
Принадлежит:

Provided herein are GPCR-based chemical biosensors that can have a sensing unit, a processing unit, and a response unit that can be used to detect a chemical of interest. Also provided herein are methods of making and using the GPCR-based chemical biosensors. 1. A biosensor comprising: 'a G-protein coupled receptor (GPCR);', 'a sensing unit, the sensing unit comprising 'a signal transduction pathway;', 'a processing unit, the processing unit comprising 'wherein the sensing unit is in biologic communication with the processing unit and the processing unit is in biologic communication with the response unit.', 'a recombinant signal molecule gene, where the recombinant signal molecule gene is operatively coupled to a promoter that is responsive to the processing unit,'}, 'a response unit, the response unit comprising2. The biosensor of claim 1 , wherein the GPCR is a heterologous GPCR.3. The biosensor of claim 2 , wherein the GPCR is codon optimized for expression in yeast.4. The biosensor of claim 1 , wherein the GPCR binds a medium chain fatty acid.5. The biosensor of claim 1 , wherein the GPCR is selected from the group consisting of: M3 muscarinic receptor claim 1 , D2S Dopamine receptor claim 1 , Beta2 Adrenergic receptor claim 1 , Beta Alanine Receoptor claim 1 , Nicotinoamide receptor claim 1 , OR56 claim 1 , Geosmin GPCR claim 1 , melatonin receptor (mel1a) claim 1 , AT1R claim 1 , OR1G1; GPR40 claim 1 , STE2 claim 1 , STE3 claim 1 , and a GPCR having an amino acid sequence about 90% to 100% identical to SEQ ID NO: 59-75.6. The biosensor of claim 1 , further comprising an amplification unit claim 1 , wherein the amplification unit is biologically coupled to the response unit.7. The biosensor of claim 1 , wherein the signal transduction pathway includes the transcription factor Ste12 or a synthetic transcription factor claim 1 , where the synthetic transcription factor has a sequence about 90%-100% identical to SEQ ID NO: 51-53.8. The biosensor of claim 7 , ...

Подробнее
Номер записи: 92
16-04-2020 дата публикации

Methods and Test Kits for Determining Male Fertility Status

Номер: US20200116707A1
Автор: CARDONA Cristina, MOODY Melissa A., Ostermeier G. Charles, SIMPSON Alana J., TRAVIS Alexander J.
Принадлежит: Androvia LifeSciences, LLC

This disclosure provides a method for determining male fertility status. The method comprises determining Glocalization patterns following induced sperm capacitation, identifying the percentage of various patterns, particularly the ratio of [(AA+APM)/total number of Glocalization patterns] and determining if the percentage of certain Glocalization patterns in response to induced capacitation is altered. Based on the change in the percentage of localization patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified. 134.-. (canceled)35. A method comprising:exposing, in vitro, a sperm sample from a male to capacitating conditions;fixing the capacitated sperm sample with a fixative for at least 0.5 hour;{'sub': 'M1', 'treating the fixed in vitro capacitated sperm sample with a labeling molecule for Glocalization patterns, wherein the labeling molecule has a detectable label;'}{'sub': M1', 'M1', 'M1', 'M1', 'M1', 'M1', 'M1', 'M1', 'M1', 'M1, 'identifying more than one Glabeled localization patterns for the labeled fixed in vitro capacitated sperm sample, said Glabeled localization patterns being an apical acrosome (AA) Glocalization pattern, an acrosomal plasma membrane (APM) Glocalization pattern, a Lined-Cell Glocalization pattern, a post acrosomal plasma membrane (PAMP) Glocalization pattern, an apical acrosome/post acrosome (AA/PA) Glocalization pattern, an intermediate (INTER) Glocalization pattern, an equatorial segment (ES) Glocalization pattern, and a diffuse (DIFF) Glocalization pattern;'}{'sub': M1', 'M1, 'assigning the apical acrosome (AA) Glocalization pattern and the acrosomal plasma membrane (APM) Glocalization pattern to a capacitated state;'}{'sub': M1', 'M1, 'determining a fertility threshold corresponding to a ratio of (i) the number of Glabeled localization patterns assigned to the capacitated state and (ii) a total number of Glabeled localization ...

Подробнее
Номер записи: 93
16-04-2020 дата публикации

Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample

Номер: US20200116743A1
Автор: Baillie Rebecca A., Watkins Steven M., Wiest Michelle M.
Принадлежит:

A method of assessing the level of triglycerides in the liver of a subject comprises determining the amount of a first lipid metabolite in a sample from the subject. The sample can be blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, bile, or cerebrospinal fluid. The first lipid metabolite is a fatty acid present in a lipid class. The lipid class is selected from the group consisting of free fatty acids, total fatty acids (TL), triglycerides (TG), cholesterol esters (CE), phosphatidylcholines (PC), and phosphatidylethanolamines (PE). 1. A method of assessing the level of triglycerides in the liver of a subject , comprising determining the amount of a first lipid metabolite in a blood , plasma , serum , isolated lipoprotein fraction , saliva , urine , lymph fluid , bile , or cerebrospinal fluid sample from the subject;wherein the first lipid metabolite is a fatty acid present in a lipid class; andwherein the lipid class is selected from the group consisting of free fatty acids, total fatty acids (TL), triglycerides (TG), cholesterol esters (CE), phosphatidylcholines (PC), and phosphatidylethanolamines (PE).2. The method of claim 1 , wherein the amount of the metabolite is the relative amount of the fatty acid to total fatty acid content in the lipids of one or more lipid classes in the sample.3. The method of claim 2 , wherein the relative amount is the mole percentage or the weight percentage of the lipid metabolite in the sample.4. The method of claim 1 , wherein the amount of the metabolite is the absolute amount of the lipid metabolite in the sample.5. The method of claim 4 , wherein the absolute amount of the metabolite is the concentration of the lipid metabolite in the sample.6. The method of claim 1 , wherein the first lipid metabolite is selected from the group consisting of: CE20:4n6; PC20:4n6; PE20:4n6; TL20:4n6; TG20:4n6; PC18:3n6; PC20:3n6; CE14:0; CE16:1n7; CE18:1n9; CEMUFA; CEn7; CE18:1n7; CE18:2n6; CE18:3n6; CE22:5n3; ...

Подробнее
Номер записи: 94
27-05-2021 дата публикации

Combination treponemal and non-treponemal syphilis test

Номер: US20210156859A1
Автор: Ravi Kaul, Roger Walker, Weiming Zheng
Принадлежит: Bio Rad Laboratories Inc

Provided herein are multiplex assays for detecting antibodies indicative of presence and stage of syphilis infection in an individual. Individuals infected with syphilis produce antibodies directed to syphilis components and the lipid cellular debris associated with the infection. The present disclosure represents the first combination of these diverse antibody targets in a single assay.

Подробнее
Номер записи: 95
12-05-2016 дата публикации

LIPID BIOMARKERS FOR STABLE AND UNSTABLE HEART DISEASE

Номер: US20160131667A1
Автор: Bedo Justin, Goudey Benjamin, Haviv Izhak, Kingwell Bronwyn Anne, Meikle Peter John
Принадлежит:

The present invention relates generally to the field of diagnostic and prognostic assays for heart disease. More particular, the present invention provides an assay for diagnosing the presence or extent of development of heart disease or its classification or state thereof. The assay of the present invention is also useful in the stratification of a subject with respect to a risk of developing heart disease. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic and reporting system. 1. A method to stratify a subject as vulnerable or non-vulnerable to plaque rupture , the method comprising determining the levels of at least two lipid analytes in a biological sample from the subject that comprises lipids , wherein the at least two lipid analytes are selected from the group consisting of: CE 14:0 , CE 15:0 , CE16:2 , CE 16:1 , CE 16:0 , CE 17:1 , CE 17:0 , CE 18:3 , CE 18:2 , CE 18:1 , CE18:0 , CE 20:5 , CE 20:4 , CE 20:3 , CE 20:2 , CE 20:1 , CE 22:6 , CE 22:5 , CE 22:4 , CE 22:3 , CE 22:2 , CE 22:1 , CE 22:0 , CE 24:6 , CE 24:5 , CE24:4 , CE 24:3 , CE 24:2 , CE 24:1 , and CE 24:0; wherein the level of the at least two lipid analytes is different between vulnerable subjects and non-vulnerable subjects and wherein the level of the at least two lipid analytes in the subject relative to a control identifies the subject as being vulnerable or non-vulnerable to plaque rupture.2. The method of claim 1 , comprising comparing the level of the at least two lipid analytes in the subject to the respective levels of the same lipid analytes in at least one control subject selected from a vulnerable subject and a non-vulnerable subject claim 1 , wherein a similarity in the respective levels of the at least two lipid analytes between the subject and the non-vulnerable subject identifies the subject as being non-vulnerable claim 1 , and wherein a similarity in the respective levels of the at least two lipid analytes ...

Подробнее
Номер записи: 96
02-05-2019 дата публикации

METHOD FOR PREVENTING OBESITY-INDUCED FATTY LIVER BY INHIBITING KCTD17

Номер: US20190125829A1
Автор: KIM KyeongJin, PAJVANI Utpal
Принадлежит: The Trustees of Columbia University in the City of New York

The present invention provides methods for reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that decreases KCTD17 expression in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels. 1. A method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that decreases KCTD17 expression in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.2. A method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that prevents PHLPP2 degradation in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.3. The method of claim 2 , wherein the pharmaceutical composition inhibits Glucagon signaling.4. A method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that inhibits Glucagon signaling in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.5. The method of claim 4 , wherein the pharmaceutical composition reduces PHLPP2 degradation.6. The method of or claim 4 , wherein the pharmaceutical composition increases free Raptor in the liver cells.7. The method of - claim 4 , wherein the pharmaceutical composition decreases PHLPP2 phosphorylation at Serine 1119 and Serine 1210 residues in liver cells.8. The method of claim 6 , wherein the pharmaceutical composition prevents PHLPP2 degradation in liver cells.9. The method of any one of - claim 6 ...

Подробнее
Номер записи: 97
11-05-2017 дата публикации

METHODS OF IDENTIFYING AND QUANTIFYING SPHINGOLIPIDS

Номер: US20170131300A1
Автор: JIANG Zhi-Hong, Mi Jia-Ning, WANG Jing-Rong
Принадлежит:

The present invention relates to a method of identifying and preferably quantifying at least one sphingolipid, in particular the sphingolipid portion in wild-type or derivates. A further aspect relates to a method of identifying wild-type in a sample as well as for identifying derivates in a sample. The methods of the present invention, thus, allow for determining the quality and safety of products and for advantageously differentiating between wild-type and derivates via the ratio and/or presence of certain sphingolipids especially suitable as markers. 1Cordyceps. A method of identifying and optionally quantifying at least one sphingolipid in a sample , which method comprises steps of:{'i': Cordyceps', 'Cordyceps, 'a) preparing a test sample solution from a sample comprising a step of (i) extracting the sample with at least a first extracting solvent, which extracting solvent comprises an aliphatic alcohol;'}b) subjecting the test sample solution to liquid chromatography with a mobile phase comprising at least a first and a second eluting solvent, wherein the at least first and second eluting solvent comprise a mixture of at least one aliphatic alcohol, at least one carboxylic acid and at least one carboxylic acid salt and wherein the second eluting solvent has a higher total amount of aliphatic alcohol compared to the first eluting solvent; andc) performing a mass spectrometry following step b).2CordycepsCordyceps. The method of claim 1 , wherein the sample is used in step a) (i) in powdered form and wherein 20 mg to 80 mg of the powdered sample are used.3. The method of claim 1 , wherein the aliphatic alcohol in step (i) is a monohydric aliphatic alcohol containing one to four carbon atoms.4. The method of claim 1 , wherein step a) comprises steps of{'i': Cordyceps', 'Cordyceps, '(i) extracting the sample with the at least first, a second and a third extracting solvent, which first, second and third extracting solvents each comprise a monohydric aliphatic alcohol ...

Подробнее
Номер записи: 98
03-06-2021 дата публикации

MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF

Номер: US20210162021A1
Автор: Chuang Wei-Lien, Cox Gerald F., Zhang X. Kate
Принадлежит: Genzyme Corporation

The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy. 115-. (canceled)16. A method of treating acid sphingomvelinase deficiency in a human subject , wherein the method comprises:administering to the subject intravenously a starting dose of recombinant human acid sphingomyelinase (rhASM) or a modified rhASM at 0.03 or 0.1 mg/kg and subsequent doses that increase in dose concentration until reaching 3 mg/kg;administering maintenance doses to the subject at 3 mg/kg or less; andmeasuring the level of lyso-sphingomyelin (lyso-SPM) in a biological sample collected from the subject (a) within 24 hours, (b) within 48 hours, or (c) 72 or more hours after administration of a dose;wherein each dose is administered two weeks after the previous dose.17. The method of claim 16 , wherein the maintenance doses are administered at 1 claim 16 , 2 claim 16 , or 3 mg/kg.18. The method of claim 16 , wherein the subject has been determined prior to treatment to have an elevated level of lyso-SPM compared to a healthy control.19. The method of claim 16 , wherein the biological sample is a dried blood spot.20. The method of claim 16 , wherein the biological sample is collected prior to a subsequent dose.2122-. (canceled) This application is a continuation of U.S. application Ser. No. 16/003,598, filed Jun. 8, 2018, which is a continuation of U.S. application Ser. No. 14/895,472, filed Dec. 2, 2015, which is a U.S. national phase application of International Application No. PCT/US2014/041405, filed Jun. 6, 2014, which claims the benefit of priority under 35 U.S.C. § 119 of U.S. Provisional Application No. 61/832,302, filed Jun. 7, 2013. The contents of the aforementioned priority applications are incorporated herein by reference in ...

Подробнее
Номер записи: 99
19-05-2016 дата публикации

TREATMENT OF AUTOPHAGY-RELATED DISORDERS

Номер: US20160136123A1
Автор: Deretic Vojo P., Mandell Michael
Принадлежит:

The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions. 1. A method of treating or reducing the likelihood of the onset of an autophagy-mediated disease in a patient in need thereof comprising administering to said patient an effective amount of a composition comprising an effective amount of an autophagy modulator selected from the group consisting of a neutral lipid , a TRIM protein or a mixtures thereof and optionally , another bioactive agent.2. The method according to wherein said autophagy modulator is a neutral lipid.3. The method according to wherein said autophagy modulator is a TRIM protein.4. The method according to wherein said neutral lipid is effective in enhancing lipid stores and promoting lipid droplets in said patient such that enhancement of autophagy occurs.5. The method according to wherein said neutral lipid is selected from the group consisting of neutral lipids selected from the group consisting of triglycerides claim 2 , diglycerides claim 2 , monoglycerides claim 2 , glycolated mono- or diacylglycerdies claim 2 , dolichol claim 2 , polyprenol claim 2 , polyprenal or very long chain fatty acids.6. The method according to wherein said autophagy modulator is a TRIM protein selected from the group consisting of TRIM5α claim 1 , TRIM1 claim 1 , TRIM6 claim 1 , TRIM10 claim 1 , TRIM17 claim 1 , TRIM22 claim 1 , TRIM41 claim 1 , TRIM55 claim 1 , TRIM72 and TRIM76 claim 1 , among others (including TRIM 1 ...

Подробнее
Номер записи: 100